J DAVID GLADSTONE INSTITUTES
Cite this
Plain text J DAVID GLADSTONE INSTITUTES. furp.org, nonprofit organization profile, tax years 2010–2024. https://furp.org/org/j-david-gladstone-institutes-237203666. Retrieved 2026-11-01.
APA furp.org. (n.d.). J DAVID GLADSTONE INSTITUTES [Nonprofit organization profile; tax years 2010–2024]. Retrieved November 1, 2026, from https://furp.org/org/j-david-gladstone-institutes-237203666
MLA “J DAVID GLADSTONE INSTITUTES.” furp.org, tax years 2010–2024, https://furp.org/org/j-david-gladstone-institutes-237203666. Accessed 1 Nov. 2026.
Retrieved 2026-11-01; covers tax years 2010–2024. Data: furp.org, CC BY 4.0.
2024 · Form 990 · revenue $119.2M · expenses $144.8M · assets $372.0M
- EIN
- 23-7203666
- Address
- 1650 OWENS ST, SAN FRANCISCO, CA 94158-2261
- Website
- WWW.GLADSTONEINSTITUTES.ORG
- NTEE code
- H900
- Exempt type
- 501(c)(3): charitable, religious, educational, scientific or literary (trust)
- Ruling date
- June 1973 (when the IRS recognized its exemption)
- IRS status
- Exempt (unconditional) (IRS Business Master File) IRS data ↗
- Tax-deductible donations
- Yes: listed in IRS Publication 78 (public charity) Pub 78 ↗
- Foundation status
- Public charity supported by the public (170(b)(1)(a)(vi))
- Cross-check
- ProPublica Nonprofit Explorer
Mission
TO DRIVE A NEW ERA OF DISCOVERY IN DISEASE ORIENTED SCIENCE AND TO MENTOR TOMORROW'S LEADERS IN AN INSPIRING AND DIVERSE ENVIRONMENT.
Each tax year counts once: when a return was amended, only the latest return for that period is used below (superseded returns stay listed, greyed, under Finances).
People paid by the organization
37 people paid across every filing: current people first, then by total pay from this organization. Organizations counts every nonprofit each person appears on.
| Name | Latest title | Years | Latest year pay | Total pay from here | Organizations |
|---|---|---|---|---|---|
| Deepak Srivastava | PRESIDENT | 2010-2024 | $1,182,258 | $12,560,033 | 2 |
| Lennart Mucke | DIRECTOR | 2010-2024 | $688,141 | $8,296,614 | 1 |
| Andrew S Garb | TRUSTEE | 2010-2024 | $425,000 | $6,787,500 | 1 |
| Stephen Freedman | VP FOR CORP LIAISON & VENTURES | 2012-2024 | $555,861 | $6,234,197 | 1 |
| Steven M Finkbeiner | DIRECTOR | 2015-2024 | $653,891 | $5,657,226 | 1 |
| Robert Obana | COO | 2016-2024 | $713,836 | $4,733,862 | 1 |
| Katherine Pollard | DIRECTOR | 2017-2024 | $623,305 | $4,253,697 | 1 |
| Benoit Bruneau | DIRECTOR | 2018-2024 | $619,182 | $3,978,946 | 1 |
| Nicholas J Simon | TRUSTEE | 2017-2024 | $425,000 | $3,106,250 | 2 |
| Melanie Ott | DIRECTOR | 2020-2024 | $643,925 | $2,915,688 | 1 |
| Alex Marson | DIRECTOR | 2020-2024 | $746,136 | $2,802,188 | 1 |
| Robert Wicks | VP OF PHILANTHROPY | 2019-2024 | $508,937 | $2,530,234 | 1 |
| Jennifer Crosby | VP OF PEOPLE SERVICES | 2021-2024 | $618,240 | $2,109,137 | 1 |
| William Price | TRUSTEE | 2016-2024 | $425,000 | $1,800,000 | 1 |
| Michelle Sibly | VP OF FINANCE | 2020-2024 | $456,873 | $1,674,202 | 1 |
| Katerina Akassoglou | SR. INVESTIGATOR | 2024 | $482,979 | $482,979 | 1 |
| Robert S Williams (former) | PRESIDENT EMERITUS | 2010-2020 | $111,533 | $7,531,092 | 1 |
| Warner Greene (former) | DIRECTOR (THRU 12/23) | 2010-2023 | $457,345 | $6,895,772 | 1 |
| Richard D Jones (former) | TRUSTEE (THRU 6/30/17) | 2010-2017 | $356,250 | $3,681,250 | 1 |
| Leor Weinberger (former) | SR. INVESTIGATOR | 2017-2023 | $577,786 | $3,598,020 | 1 |
| Robert W Mahley (former) | President Emeritus | 2010-2016 | $466,578 | $3,416,276 | 1 |
| Albert A Dorman (former) | Trustee (Thru 06/30) | 2010-2016 | $356,250 | $3,206,250 | 1 |
| Eric M Verdin (former) | Sr. Investigator | 2010-2016 | $452,102 | $2,909,067 | 1 |
| Todd Mcdevitt (former) | SR. INVESTIGATOR | 2015-2020 | $384,719 | $1,472,464 | 1 |
| John Whiting (former) | VP, CAO, CFO | 2011-2014 | $390,018 | $1,394,983 | 1 |
| Vincent S Moseley (former) | CFO,VP OF FINANCE (THRU 10/15/2017) | 2015-2017 | $425,309 | $1,215,972 | 1 |
| Richard Hille (former) | EXECUTIVE DIRECTOR | 2010-2011 | $699,653 | $1,071,806 | 1 |
| Hal Orr (former) | CFO | 2010-2011 | $548,298 | $854,755 | 1 |
| Stephen Finkbeiner (former) | SR. INVESTIGATOR | 2013-2014 | $383,470 | $715,572 | 1 |
| Vincent E Moseley (former) | VP FOR FINANCE | 2012-2013 | $330,300 | $669,860 | 1 |
| Daniel Oshiro (former) | V.P. OF OPERATIONS | 2010-2011 | $324,619 | $642,047 | 1 |
| Megan Mcdevitt (former) | VP OF COMMUNICATIONS (THRU 11/22) | 2022 | $444,981 | $444,981 | 1 |
| Benoit Brueau (former) | ASSOCIATE DIRECTOR | 2017 | $420,025 | $420,025 | 1 |
| Saptarsi Haldar (former) | Associate Investigator | 2016 | $374,607 | $374,607 | 1 |
| Virginia Saifer (former) | CHIEF DEVELOPMENT OFFICER | 2012 | $358,821 | $358,821 | 1 |
| Ann L Carollo (former) | VP OF PHILANTHROPY AND PUBLIC RELATIONS | 2014 | $313,120 | $313,120 | 1 |
| JOHN WHITING Through 43015 (former) | VP, Cao, cfo | 2015 | $161,363 | $161,363 | 1 |
People by year
2024 · 16 people listed · 16 paid, $9.8M · 593 employees · 90 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| DEEPAK SRIVASTAVA | PRESIDENT | 40 | $1,088,619 | $0 | $93,639 | $1,182,258 | 2 |
| ALEX MARSON | DIRECTOR | 40 | $669,747 | $0 | $76,389 | $746,136 | 1 |
| ROBERT OBANA | COO | 40 | $631,301 | $0 | $82,535 | $713,836 | 1 |
| LENNART MUCKE | DIRECTOR | 40 | $621,959 | $0 | $66,182 | $688,141 | 1 |
| STEVEN M FINKBEINER | DIRECTOR | 40 | $565,340 | $0 | $88,551 | $653,891 | 1 |
| MELANIE OTT | DIRECTOR | 40 | $550,286 | $0 | $93,639 | $643,925 | 1 |
| KATHERINE POLLARD | DIRECTOR | 40 | $529,666 | $0 | $93,639 | $623,305 | 1 |
| BENOIT BRUNEAU | DIRECTOR | 40 | $525,543 | $0 | $93,639 | $619,182 | 1 |
| JENNIFER CROSBY | VP OF PEOPLE SERVICES | 40 | $491,851 | $0 | $126,389 | $618,240 | 1 |
| STEPHEN FREEDMAN | VP FOR CORP LIAISON & VENTURES | 40 | $489,679 | $0 | $66,182 | $555,861 | 1 |
| ROBERT WICKS | VP OF PHILANTHROPY | 40 | $448,823 | $0 | $60,114 | $508,937 | 1 |
| KATERINA AKASSOGLOU | SR. INVESTIGATOR | 40 | $389,340 | $0 | $93,639 | $482,979 | 1 |
| MICHELLE SIBLY | VP OF FINANCE | 40 | $375,123 | $0 | $81,750 | $456,873 | 1 |
| ANDREW S GARB | TRUSTEE | 3 | $425,000 | $0 | $0 | $425,000 | 1 |
| WILLIAM PRICE | TRUSTEE | 3 | $425,000 | $0 | $0 | $425,000 | 1 |
| NICHOLAS J SIMON | TRUSTEE | 3 | $425,000 | $0 | $0 | $425,000 | 2 |
2023 · 17 people listed · 17 paid, $10.1M · 581 employees · 126 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| DEEPAK SRIVASTAVA | PRESIDENT | 40 | $1,209,292 | $0 | $91,079 | $1,300,371 | 2 |
| ROBERT OBANA | COO | 40 | $613,776 | $0 | $80,030 | $693,806 | 1 |
| LENNART MUCKE | DIRECTOR | 40 | $600,802 | $0 | $63,851 | $664,653 | 1 |
| STEVEN M FINKBEINER | DIRECTOR | 40 | $544,316 | $0 | $91,079 | $635,395 | 1 |
| MELANIE OTT | DIRECTOR | 40 | $534,623 | $0 | $91,079 | $625,702 | 1 |
| ALEX MARSON | DIRECTOR | 40 | $530,966 | $0 | $77,012 | $607,978 | 1 |
| BENOIT BRUNEAU | DIRECTOR | 40 | $506,804 | $0 | $91,079 | $597,883 | 1 |
| KATHERINE POLLARD | DIRECTOR | 40 | $489,200 | $0 | $89,333 | $578,533 | 1 |
| LEOR WEINBERGER | SR. INVESTIGATOR | 40 | $486,707 | $0 | $91,079 | $577,786 | 1 |
| JENNIFER CROSBY | VP OF PEOPLE SERVICES | 40 | $470,611 | $0 | $74,579 | $545,190 | 1 |
| STEPHEN FREEDMAN | VP FOR CORP LIAISON & VENTURES | 40 | $473,173 | $0 | $63,851 | $537,024 | 1 |
| MICHELLE SIBLY | VP OF FINANCE | 40 | $436,597 | $0 | $49,500 | $486,097 | 1 |
| ROBERT WICKS | VP OF PHILANTHROPY | 40 | $427,001 | $0 | $56,587 | $483,588 | 1 |
| WARNER GREENE | DIRECTOR (THRU 12/23) | 40 | $377,315 | $0 | $80,030 | $457,345 | 1 |
| NICHOLAS J SIMON | TRUSTEE | 3 | $425,000 | $0 | $0 | $425,000 | 2 |
| ANDREW S GARB | TRUSTEE | 3 | $425,000 | $0 | $0 | $425,000 | 1 |
| WILLIAM PRICE | TRUSTEE | 3 | $425,000 | $0 | $0 | $425,000 | 1 |
2022 · 17 people listed · 17 paid, $9.7M · 579 employees · 110 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| DEEPAK SRIVASTAVA | PRESIDENT | 40 | $1,027,331 | $0 | $84,948 | $1,112,279 | 2 |
| ROBERT OBANA | COO | 40 | $597,259 | $0 | $74,437 | $671,696 | 1 |
| LENNART MUCKE | DIRECTOR | 40 | $576,250 | $0 | $59,310 | $635,560 | 1 |
| STEVEN M FINKBEINER | DIRECTOR | 40 | $526,485 | $0 | $84,948 | $611,433 | 1 |
| MELANIE OTT | DIRECTOR | 40 | $518,779 | $0 | $84,948 | $603,727 | 1 |
| WARNER GREENE | DIRECTOR | 40 | $522,014 | $0 | $74,437 | $596,451 | 1 |
| BENOIT BRUNEAU | DIRECTOR | 40 | $510,630 | $0 | $84,948 | $595,578 | 1 |
| ALEX MARSON | DIRECTOR | 40 | $522,391 | $0 | $46,016 | $568,407 | 1 |
| LEOR WEINBERGER | SR. INVESTIGATOR | 40 | $475,427 | $0 | $84,948 | $560,375 | 1 |
| KATHERINE POLLARD | DIRECTOR | 40 | $471,857 | $0 | $84,948 | $556,805 | 1 |
| STEPHEN FREEDMAN | VP FOR CORP LIAISON & VENTURES | 40 | $457,423 | $0 | $59,875 | $517,298 | 1 |
| JENNIFER CROSBY | VP OF PEOPLE SERVICES | 40 | $432,788 | $0 | $69,698 | $502,486 | 1 |
| ROBERT WICKS | VP OF PHILANTHROPY | 40 | $411,899 | $0 | $37,032 | $448,931 | 1 |
| MEGAN MCDEVITT | VP OF COMMUNICATIONS (THRU 11/22) | 40 | $399,332 | $0 | $45,649 | $444,981 | 1 |
| NICHOLAS J SIMON | TRUSTEE | 3 | $425,000 | $0 | $0 | $425,000 | 2 |
| ANDREW S GARB | TRUSTEE | 3 | $425,000 | $0 | $0 | $425,000 | 1 |
| WILLIAM PRICE | TRUSTEE | 3 | $425,000 | $0 | $0 | $425,000 | 1 |
2021 · 17 people listed · 17 paid, $8.9M · 530 employees · 85 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| DEEPAK SRIVASTAVA | PRESIDENT | 40 | $1,005,808 | $0 | $77,666 | $1,083,474 | 2 |
| LENNART MUCKE | DIRECTOR | 40 | $559,420 | $0 | $55,337 | $614,757 | 1 |
| ROBERT OBANA | COO | 40 | $538,250 | $0 | $68,517 | $606,767 | 1 |
| STEVEN M FINKBEINER | DIRECTOR | 40 | $512,829 | $0 | $77,666 | $590,495 | 1 |
| WARNER GREENE | DIRECTOR | 40 | $512,441 | $0 | $68,517 | $580,958 | 1 |
| BENOIT BRUNEAU | DIRECTOR | 40 | $496,795 | $0 | $77,666 | $574,461 | 1 |
| MELANIE OTT | DIRECTOR | 40 | $480,052 | $0 | $77,666 | $557,718 | 1 |
| ALEX MARSON | DIRECTOR | 40 | $510,740 | $0 | $38,757 | $549,497 | 1 |
| KATHERINE POLLARD | DIRECTOR | 40 | $458,517 | $0 | $77,666 | $536,183 | 1 |
| LEOR WEINBERGER | SR. INVESTIGATOR | 40 | $442,323 | $0 | $77,666 | $519,989 | 1 |
| STEPHEN FREEDMAN | VP FOR CORP LIAISON & VENTURES | 40 | $441,425 | $0 | $68,517 | $509,942 | 1 |
| JENNIFER CROSBY | VP OF PEOPLE SERVICES | 40 | $409,055 | $0 | $34,166 | $443,221 | 1 |
| ANDREW S GARB | TRUSTEE | 3 | $425,000 | $0 | $0 | $425,000 | 1 |
| NICHOLAS J SIMON | TRUSTEE | 3 | $425,000 | $0 | $0 | $425,000 | 2 |
| ROBERT WICKS | VP OF PHILANTHROPY | 40 | $356,964 | $0 | $35,303 | $392,267 | 1 |
| MICHELLE SIBLY | VP OF FINANCE | 40 | $325,069 | $0 | $43,500 | $368,569 | 1 |
| WILLIAM PRICE | TRUSTEE | 3 | $100,000 | $0 | $0 | $100,000 | 1 |
2020 · 18 people listed · 18 paid, $8.3M · 473 employees · 40 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| DEEPAK SRIVASTAVA | PRESIDENT | 40 | $975,518 | $0 | $72,499 | $1,048,017 | 2 |
| LENNART MUCKE | DIRECTOR | 40 | $544,659 | $0 | $53,080 | $597,739 | 1 |
| STEVEN M FINKBEINER | DIRECTOR | 40 | $496,678 | $0 | $72,499 | $569,177 | 1 |
| ROBERT OBANA | COO | 40 | $496,259 | $0 | $50,293 | $546,552 | 1 |
| BENOIT BRUNEAU | DIRECTOR | 40 | $461,824 | $0 | $72,499 | $534,323 | 1 |
| KATHERINE POLLARD | DIRECTOR | 40 | $444,539 | $0 | $72,499 | $517,038 | 1 |
| WARNER GREENE | DIRECTOR | 40 | $438,619 | $0 | $64,543 | $503,162 | 1 |
| LEOR WEINBERGER | SR. INVESTIGATOR | 40 | $424,886 | $0 | $72,499 | $497,385 | 1 |
| STEPHEN FREEDMAN | VP FOR CORP LIAISON & VENTURES | 40 | $429,571 | $0 | $64,543 | $494,114 | 1 |
| MELANIE OTT | DIRECTOR | 40 | $412,117 | $0 | $72,499 | $484,616 | 1 |
| NICHOLAS J SIMON | TRUSTEE | 3 | $425,000 | $0 | $0 | $425,000 | 2 |
| ANDREW S GARB | TRUSTEE | 3 | $425,000 | $0 | $0 | $425,000 | 1 |
| TODD MCDEVITT | SR. INVESTIGATOR | 40 | $331,639 | $0 | $53,080 | $384,719 | 1 |
| ROBERT WICKS | VP OF PHILANTHROPY | 40 | $332,124 | $0 | $34,403 | $366,527 | 1 |
| MICHELLE SIBLY | VP OF FINANCE | 40 | $319,913 | $0 | $42,750 | $362,663 | 1 |
| ALEX MARSON | DIRECTOR | 40 | $323,852 | $0 | $6,318 | $330,170 | 1 |
| ROBERT S WILLIAMS | PRESIDENT EMERITUS | 40 | $76,570 | $0 | $34,963 | $111,533 | 1 |
| WILLIAM PRICE | TRUSTEE | 3 | $100,000 | $0 | $0 | $100,000 | 1 |
2019 · 15 people listed · 15 paid, $7.1M · 485 employees · 100 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| DEEPAK SRIVASTAVA | PRESIDENT | 40 | $937,990 | $0 | $65,818 | $1,003,808 | 2 |
| BENOIT BRUNEAU | DIRECTOR | 40 | $545,942 | $0 | $65,818 | $611,760 | 1 |
| STEVEN M FINKBEINER | SR. INVESTIGATOR | 40 | $490,332 | $0 | $65,818 | $556,150 | 1 |
| WARNER GREENE | DIRECTOR | 40 | $455,389 | $0 | $59,267 | $514,656 | 1 |
| KATHERINE POLLARD | DIRECTOR | 40 | $438,881 | $0 | $65,818 | $504,699 | 1 |
| ROBERT OBANA | COO | 40 | $453,564 | $0 | $45,517 | $499,081 | 1 |
| LENNART MUCKE | DIRECTOR | 40 | $441,740 | $0 | $49,796 | $491,536 | 1 |
| LEOR WEINBERGER | SR. INVESTIGATOR | 40 | $422,183 | $0 | $65,818 | $488,001 | 1 |
| STEPHEN FREEDMAN | VP FOR CORP LIAISON & VENTURES | 40 | $424,664 | $0 | $59,267 | $483,931 | 1 |
| ANDREW S GARB | TRUSTEE | 3 | $425,000 | $0 | $0 | $425,000 | 1 |
| NICHOLAS J SIMON | TRUSTEE | 3 | $425,000 | $0 | $0 | $425,000 | 2 |
| TODD MCDEVITT | SR. INVESTIGATOR | 40 | $326,883 | $0 | $36,046 | $362,929 | 1 |
| ROBERT WICKS | VP OF PHILANTHROPY | 40 | $324,401 | $0 | $5,583 | $329,984 | 1 |
| ROBERT S WILLIAMS | PRESIDENT EMERITUS | 40 | $232,119 | $0 | $59,267 | $291,386 | 1 |
| WILLIAM PRICE | TRUSTEE | 3 | $100,000 | $0 | $0 | $100,000 | 1 |
2018 · 14 people listed · 14 paid, $6.8M · 490 employees · 110 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| DEEPAK SRIVASTAVA | PRESIDENT | 40 | $884,245 | $0 | $67,827 | $952,072 | 2 |
| LENNART MUCKE | DIRECTOR | 40 | $587,339 | $0 | $50,437 | $637,776 | 1 |
| STEVEN M FINKBEINER | SR. INVESTIGATOR | 40 | $476,122 | $0 | $67,827 | $543,949 | 1 |
| WARNER GREENE | DIRECTOR | 40 | $469,118 | $0 | $60,723 | $529,841 | 1 |
| LEOR WEINBERGER | SR INVESTIGATOR | 40 | $436,683 | $0 | $67,827 | $504,510 | 1 |
| KATHERINE POLLARD | DIRECTOR | 40 | $425,810 | $0 | $67,827 | $493,637 | 1 |
| STEPHEN FREEDMAN | VP FOR CORP LIAISON & VENTURES | 40 | $424,664 | $0 | $60,723 | $485,387 | 1 |
| ROBERT OBANA | COO | 40 | $415,984 | $0 | $46,973 | $462,957 | 1 |
| ROBERT S WILLIAMS | PRESIDENT EMERITUS | 40 | $386,124 | $0 | $60,723 | $446,847 | 1 |
| BENOIT BRUNEAU | ASSOCIATE DIRECTOR | 40 | $377,932 | $0 | $67,827 | $445,759 | 1 |
| NICHOLAS J SIMON | TRUSTEE | 15 | $437,500 | $0 | $0 | $437,500 | 2 |
| ANDREW S GARB | TRUSTEE | 15 | $437,500 | $0 | $0 | $437,500 | 1 |
| TODD MCDEVITT | SR. INVESTIGATOR | 40 | $318,147 | $0 | $36,687 | $354,834 | 1 |
| WILLIAM PRICE | TRUSTEE | 15 | $100,000 | $0 | $0 | $100,000 | 1 |
2017 · 15 people listed · 15 paid, $6.8M · 487 employees · 90 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| ROBERT S WILLIAMS | PRESIDENT (THRU 12/31/17) | 40 | $831,432 | $0 | $60,723 | $892,155 | 1 |
| DEEPAK SRIVASTAVA | DIRECTOR | 40 | $590,775 | $0 | $67,827 | $658,602 | 2 |
| LENNART MUCKE | DIRECTOR | 40 | $503,204 | $0 | $50,437 | $553,641 | 1 |
| STEVEN M FINKBEINER | SR. INVESTIGATOR | 40 | $461,213 | $0 | $67,827 | $529,040 | 1 |
| WARNER GREENE | DIRECTOR | 40 | $455,722 | $0 | $60,723 | $516,445 | 1 |
| STEPHEN FREEDMAN | VP FOR CORP LIAISON & VENTURES | 40 | $414,427 | $0 | $60,723 | $475,150 | 1 |
| ANDREW S GARB | TRUSTEE | 15 | $475,000 | $0 | $0 | $475,000 | 1 |
| LEOR WEINBERGER | SR INVESTIGATOR | 40 | $384,751 | $0 | $65,223 | $449,974 | 1 |
| KATHERINE POLLARD | SR INVESTIGATOR - LEAD SCIENTIST | 40 | $375,670 | $0 | $67,827 | $443,497 | 1 |
| VINCENT S MOSELEY | CFO,VP OF FINANCE (THRU 10/15/2017) | 40 | $358,404 | $0 | $66,905 | $425,309 | 1 |
| BENOIT BRUEAU | ASSOCIATE DIRECTOR | 40 | $352,198 | $0 | $67,827 | $420,025 | 1 |
| ROBERT OBANA | COO | 40 | $364,097 | $0 | $19,473 | $383,570 | 1 |
| RICHARD D JONES | TRUSTEE (THRU 6/30/17) | 15 | $356,250 | $0 | $0 | $356,250 | 1 |
| NICHOLAS J SIMON | TRUSTEE | 15 | $118,750 | $0 | $0 | $118,750 | 2 |
| WILLIAM PRICE | TRUSTEE | 15 | $100,000 | $0 | $0 | $100,000 | 1 |
2016 · 15 people listed · 15 paid, $6.6M · 482 employees · 87 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| Robert S Williams | President | 40 | $812,380 | $0 | $58,179 | $870,559 | 1 |
| Deepak Srivastava | Director | 40 | $491,160 | $0 | $64,902 | $556,062 | 2 |
| Lennart Mucke | Director | 40 | $488,850 | $0 | $48,444 | $537,294 | 1 |
| Steven M Finkbeiner | Sr. Investigator | 40 | $459,849 | $0 | $64,902 | $524,751 | 1 |
| Warner Greene | Director | 40 | $445,470 | $0 | $58,179 | $503,649 | 1 |
| Richard D Jones | Trustee | 15 | $475,000 | $0 | $0 | $475,000 | 1 |
| Andrew S Garb | Trustee | 15 | $475,000 | $0 | $0 | $475,000 | 1 |
| Robert W Mahley | President Emeritus | 40 | $408,399 | $0 | $58,179 | $466,578 | 1 |
| Stephen Freedman | VP for Corp Liaison & Ventures | 40 | $404,770 | $0 | $58,179 | $462,949 | 1 |
| Eric M Verdin | Sr. Investigator | 40 | $387,200 | $0 | $64,902 | $452,102 | 1 |
| Vincent S Moseley | CFO, VP of Finance | 40 | $347,630 | $0 | $64,902 | $412,532 | 1 |
| Saptarsi Haldar | Associate Investigator | 40 | $349,455 | $0 | $25,152 | $374,607 | 1 |
| Albert A Dorman | Trustee (Thru 06/30) | 15 | $356,250 | $0 | $0 | $356,250 | 1 |
| Robert Obana | COO | 40 | $147,483 | $0 | $8,114 | $155,597 | 1 |
| William Price | Trustee | 15 | $25,000 | $0 | $0 | $25,000 | 1 |
2015 · 14 people listed · 14 paid, $6.6M · 503 employees · 85 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| ROBERT S WILLIAMS | PRESIDENT | 40 | $779,544 | $0 | $51,126 | $830,670 | 1 |
| DEEPAK SRIVASTAVA | Director | 40 | $571,792 | $0 | $55,395 | $627,187 | 2 |
| LENNART MUCKE | DIRECTOR | 40 | $476,990 | $0 | $44,801 | $521,791 | 1 |
| WARNER GREENE | Director | 40 | $434,790 | $0 | $51,126 | $485,916 | 1 |
| ROBERT MAHLEY | PRESIDENT EMERITUS | 40 | $425,590 | $0 | $51,126 | $476,716 | 1 |
| ALBERT A DORMAN | TRUSTEE | 25 | $475,000 | $0 | $0 | $475,000 | 1 |
| ANDREW S GARB | TRUSTEE | 25 | $475,000 | $0 | $0 | $475,000 | 1 |
| RICHARD D JONES | TRUSTEE | 25 | $475,000 | $0 | $0 | $475,000 | 1 |
| STEPHEN FREEDMAN | VP FOR CORP LIAISON & VENT | 40 | $414,990 | $0 | $37,626 | $452,616 | 1 |
| ERIC VERDIN | SENIOR INVESTIGATOR | 40 | $393,207 | $0 | $55,395 | $448,602 | 1 |
| STEVEN FINKBEINER | SR. INVESTIGATOR | 40 | $387,550 | $0 | $55,395 | $442,945 | 1 |
| VINCENT S MOSELEY | CFO AND VP OF FINANCE | 40 | $322,736 | $0 | $55,395 | $378,131 | 1 |
| Todd C McDevitt | SENIOR INVESTIGATOR | 40 | $364,181 | $0 | $5,801 | $369,982 | 1 |
| JOHN WHITING Through 43015 | VP, Cao, cfo | 40 | $129,653 | $0 | $31,710 | $161,363 | 1 |
2014 · 13 people listed · 13 paid, $6.2M · 508 employees · 85 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| ROBERT S WILLIAMS | PRESIDENT | 40 | $727,580 | $0 | $106,424 | $834,004 | 1 |
| DEEPAK SRIVASTAVA | DIRECTOR | 40 | $553,925 | $0 | $57,739 | $611,664 | 2 |
| LENNART MUCKE | DIRECTOR | 40 | $448,084 | $0 | $45,456 | $493,540 | 1 |
| ALBERT A DORMAN | TRUSTEE | 25 | $475,000 | $0 | $0 | $475,000 | 1 |
| RICHARD D JONES | TRUSTEE | 25 | $475,000 | $0 | $0 | $475,000 | 1 |
| ANDREW S GARB | TRUSTEE | 25 | $475,000 | $0 | $0 | $475,000 | 1 |
| WARNER GREENE | DIRECTOR | 40 | $407,519 | $0 | $52,581 | $460,100 | 1 |
| ROBERT MAHLEY | PRESIDENT EMERITUS | 40 | $404,135 | $0 | $52,581 | $456,716 | 1 |
| ERIC VERDIN | SENIOR INVESTIGATOR | 40 | $376,268 | $0 | $57,618 | $433,886 | 1 |
| STEPHEN FREEDMAN | VP FOR CORP LIAISON & VENT | 40 | $357,081 | $0 | $39,797 | $396,878 | 1 |
| JOHN WHITING | VP, CAO, CFO | 40 | $345,029 | $0 | $44,989 | $390,018 | 1 |
| STEPHEN FINKBEINER | SR. INVESTIGATOR | 40 | $325,789 | $0 | $57,681 | $383,470 | 1 |
| ANN L CAROLLO | VP OF PHILANTHROPY AND PUBLIC RELATIONS | 40 | $305,952 | $0 | $7,168 | $313,120 | 1 |
2013 · 13 people listed · 13 paid, $6.0M · 534 employees · 85 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| ROBERT S WILLIAMS | PRESIDENT | 40 | $699,671 | $0 | $82,316 | $781,987 | 1 |
| DEEPAK SRIVASTAVA | LAB DIRECTOR | 40 | $539,390 | $0 | $56,145 | $595,535 | 2 |
| LENNART MUCKE | LAB DIRECTOR | 40 | $431,434 | $0 | $44,420 | $475,854 | 1 |
| ALBERT A DORMAN | TRUSTEE | 25 | $475,000 | $0 | $0 | $475,000 | 1 |
| RICHARD D JONES | TRUSTEE | 25 | $475,000 | $0 | $0 | $475,000 | 1 |
| ANDREW S GARB | TRUSTEE | 25 | $475,000 | $0 | $0 | $475,000 | 1 |
| WARNER GREENE | LAB DIRECTOR | 40 | $394,494 | $0 | $51,238 | $445,732 | 1 |
| ROBERT MAHLEY | PRESIDENT EMERITUS | 40 | $390,358 | $0 | $51,238 | $441,596 | 1 |
| ERIC VERDIN | SENIOR INVESTIGATOR | 40 | $378,662 | $0 | $56,145 | $434,807 | 1 |
| STEPHEN FREEDMAN | VP FOR CORP LIAISON & VENT | 40 | $354,182 | $0 | $38,738 | $392,920 | 1 |
| JOHN WHITING | VP, CHIEF ADMIN OFFICER, C | 40 | $345,404 | $0 | $43,645 | $389,049 | 1 |
| STEPHEN FINKBEINER | SR. INVESTIGATOR | 40 | $275,957 | $0 | $56,145 | $332,102 | 1 |
| VINCENT E MOSELEY | VP FOR FINANCE | 40 | $274,235 | $0 | $56,065 | $330,300 | 1 |
2012 · 13 people listed · 13 paid, $6.1M · 485 employees · 85 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| ROBERT S WILLIAMS | PRESIDENT | 40 | $675,624 | $0 | $81,928 | $757,552 | 1 |
| DEEPAK SRIVASTAVA | LAB DIRECTOR | 40 | $506,762 | $0 | $52,845 | $559,607 | 2 |
| ROBERT MAHLEY | PRESIDENT EMERITUS | 40 | $440,298 | $0 | $50,941 | $491,239 | 1 |
| ALBERT A DORMAN | TRUSTEE | 40 | $475,000 | $0 | $0 | $475,000 | 1 |
| RICHARD D JONES | TRUSTEE | 40 | $475,000 | $0 | $0 | $475,000 | 1 |
| ANDREW S GARB | TRUSTEE | 40 | $475,000 | $0 | $0 | $475,000 | 1 |
| STEPHEN FREEDMAN | VP FOR CORP LIAISON & VENTURES | 40 | $431,801 | $0 | $38,326 | $470,127 | 1 |
| LENNART MUCKE | LAB DIRECTOR | 40 | $418,354 | $0 | $44,434 | $462,788 | 1 |
| ERIC VERDIN | SENIOR INVESTIGATOR | 40 | $389,691 | $0 | $52,750 | $442,441 | 1 |
| WARNER GREENE | LAB DIRECTOR | 40 | $382,710 | $0 | $50,941 | $433,651 | 1 |
| JOHN WHITING | VP, CHIEF ADMIN OFFICER, CFO | 40 | $320,689 | $0 | $40,945 | $361,634 | 1 |
| VIRGINIA SAIFER | CHIEF DEVELOPMENT OFFICER | 40 | $324,497 | $0 | $34,324 | $358,821 | 1 |
| VINCENT E MOSELEY | VP FOR FINANCE | 40 | $286,207 | $0 | $53,353 | $339,560 | 1 |
2011 · 13 people listed · 13 paid, $6.4M · 474 employees · 85 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| ROBERT S WILLIAMS | PRESIDENT | 40 | $781,660 | $0 | $70,234 | $851,894 | 1 |
| RICHARD HILLE | EXECUTIVE DIRECTOR | 40 | $660,402 | $0 | $39,251 | $699,653 | 1 |
| DEEPAK SRIVASTAVA | LAB DIRECTOR | 40 | $505,364 | $0 | $43,146 | $548,510 | 2 |
| HAL ORR | CFO | 40 | $506,745 | $0 | $41,553 | $548,298 | 1 |
| ALBERT A DORMAN | TRUSTEE | 40 | $475,000 | $0 | $0 | $475,000 | 1 |
| RICHARD D JONES | TRUSTEE | 40 | $475,000 | $0 | $0 | $475,000 | 1 |
| ANDREW S GARB | TRUSTEE | 40 | $475,000 | $0 | $0 | $475,000 | 1 |
| LENNART MUCKE | LAB DIRECTOR | 40 | $428,157 | $0 | $40,214 | $468,371 | 1 |
| ROBERT MAHLEY | SR. INVESTIGATOR & PRES. EMERITUS | 40 | $419,636 | $0 | $41,713 | $461,349 | 1 |
| WARNER GREENE | LAB DIRECTOR | 40 | $389,196 | $0 | $41,713 | $430,909 | 1 |
| ERIC VERDIN | SENIOR INVESTIGATOR | 40 | $349,428 | $0 | $43,035 | $392,463 | 1 |
| DANIEL OSHIRO | V.P. OF OPERATIONS | 40 | $282,963 | $0 | $41,656 | $324,619 | 1 |
| JOHN WHITING | VP, CFO | 40 | $245,633 | $0 | $8,649 | $254,282 | 1 |
2010 · 12 people listed · 12 paid, $5.8M · 399 employees · 85 volunteers
| Name | Title | Hrs/wk | From org | From related | Other | Total | Orgs |
|---|---|---|---|---|---|---|---|
| ROBERT S WILLIAMS | PRESIDENT | 40 | $792,228 | $0 | $70,277 | $862,505 | 1 |
| DEEPAK SRIVASTAVA | LAB DIRECTOR | 40 | $666,877 | $0 | $53,710 | $720,587 | 2 |
| ROBERT MAHLEY | PRESIDENT EMERITUS | 40 | $572,254 | $0 | $49,828 | $622,082 | 1 |
| ALBERT A DORMAN | TRUSTEE | 40 | $475,000 | $0 | $0 | $475,000 | 1 |
| RICHARD D JONES | TRUSTEE | 40 | $475,000 | $0 | $0 | $475,000 | 1 |
| ANDREW S GARB | TRUSTEE | 40 | $475,000 | $0 | $0 | $475,000 | 1 |
| LENNART MUCKE | LAB DIRECTOR | 40 | $409,381 | $0 | $43,792 | $453,173 | 1 |
| WARNER GREENE | LAB DIRECTOR | 40 | $384,203 | $0 | $52,754 | $436,957 | 1 |
| RICHARD HILLE | EXECUTIVE DIRECTOR | 40 | $326,634 | $0 | $45,519 | $372,153 | 1 |
| DANIEL OSHIRO | V.P. OF OPERATIONS | 40 | $274,804 | $0 | $42,624 | $317,428 | 1 |
| HAL ORR | CFO | 40 | $258,792 | $0 | $47,665 | $306,457 | 1 |
| ERIC VERDIN | SENIOR INVESTIGATOR | 40 | $245,716 | $0 | $59,050 | $304,766 | 1 |
Highest-paid independent contractors
2024 · 5 contractors · $1.9M
| Name | Location | Service | Paid |
|---|---|---|---|
| SERVICE BY MEDALLION | MOUNTAIN VIEW, CA | CUSTODIAL SERVICES | $640,917 |
| SCHWEGMAN LUNDBERG WOESSNER | MINNEAPOLIS, MN | LEGAL SERVICES | $609,129 |
| MOSS ADAMS LLP | PASADENA, CA | ACCOUNTING SERVICES | $259,626 |
| GOODWIN PROCTER LLP | PHILADELPHIA, PA | LEGAL SERVICES | $216,990 |
| DG ARCHITECTS INC | LOS ANGELES, CA | ARCHITECTURAL SERVICES | $197,129 |
2023 · 5 contractors · $3.1M
| Name | Location | Service | Paid |
|---|---|---|---|
| DG ARCHITECTS INC | MOUNTAIN VIEW, CA | ARCHITECTURAL SERVICES | $965,433 |
| SERVICE BY MEDALLION | MOUNTAIN VIEW, CA | CUSTODIAL SERVICES | $657,816 |
| SCHWEGMAN LUNDBERG WOESSNER | MINNEAPOLIS, MN | LEGAL SERVICES | $616,430 |
| BACH CONSTRUCTION INC | BURLINGAME, CA | CONSTRUCTION SERVICES | $521,743 |
| FURNITURE CONSULTANTS BOSTON | NEW YORK, NY | FABRICATION/INSTALLATION OF LAB BENCHES | $357,446 |
2022 · 5 contractors · $2.0M
| Name | Location | Service | Paid |
|---|---|---|---|
| SCHWEGMAN LUNDBERG WOESSNER | MINNEAPOLIS, MN | LEGAL SERVICES | $728,186 |
| SERVICE BY MEDALLION | MOUNTAIN VIEW, CA | CUSTODIAL SERVICES | $657,116 |
| DG ARCHITECTS INC | MOUNTAIN VIEW, CA | ARCHITECTURAL SERVICES | $251,473 |
| MOSS ADAMS LLP | PASADENA, CA | ACCOUNTING SERVICES | $194,277 |
| GOODWIN PROCTER LLP | REDWOOD CITY, CA | LEGAL SERVICES | $146,259 |
2021 · 5 contractors · $1.7M
| Name | Location | Service | Paid |
|---|---|---|---|
| SERVICE BY MEDALLION | MOUNTAIN VIEW, CA | CUSTODIAL SERVICES | $617,236 |
| SCHWEGMAN LUNDBERG WOESSNER | MINNEAPOLIS, MN | LEGAL SERVICES | $462,779 |
| METROPOLITAN ELECTRICAL CONSTRUCTION INC | SAN FRANCISCO, CA | CONSTRUCTION SERVICES | $260,372 |
| MOSS-ADAMS LLP | PASADENA, CA | ACCOUNTING SERVICES | $216,180 |
| BACH CONSTRUCTION INC | BURLINGAME, CA | CONSTRUCTION SERVICES | $156,144 |
2020 · 5 contractors · $1.5M
| Name | Location | Service | Paid |
|---|---|---|---|
| SERVICE BY MEDALLION | MOUNTAIN VIEW, CA | CUSTODIAL SERVICES | $460,316 |
| ELLUCIAN COMPANY LP | CHICAGO, IL | CONSULTING | $321,249 |
| SCHWEGMAN LUNDBERG WOESSNER | MINNEAPOLIS, MN | LEGAL SERVICES | $306,395 |
| NAVIGATOR MANAGEMENT PARTNERS LLC | COLUMBUS, OH | CONSULTING | $275,813 |
| MOSS-ADAMS LLP | PASADENA, CA | ACCOUNTING SERVICES | $185,731 |
2019 · 5 contractors · $1.8M
| Name | Location | Service | Paid |
|---|---|---|---|
| NAVIGATOR MANAGEMENT PARTNERS LLC | COLUMBUS, OH | CONSULTING | $741,414 |
| ELLUCIAN COMPANY LP | CHICAGO, IL | CONSULTING | $428,207 |
| BOZICEVIC FIELD AND FRANCIS | REDWOOD CITY, CA | LEGAL SERVICES | $303,584 |
| MOSS ADAMS LLP | PASADENA, CA | ACCOUNTING SERVICES | $186,335 |
| GOODWIN PROCTOR LLP | REDWOOD CITY, CA | LEGAL SERVICES | $111,034 |
2018 · 4 contractors · $1.0M
| Name | Location | Service | Paid |
|---|---|---|---|
| ELLUCIAN COMPANY LP | MALVERN, PA | CONSULTING SERVICES | $377,531 |
| BOZICEVIC FIELD AND FRANCIS | EAST PALO ALTO, CA | LEGAL SERVICES | $254,034 |
| DLA PIPER LLP (US) | BALTIMORE, MD | LEGAL SERVICES | $253,685 |
| MOSS ADAMS LLP | SAN DIEGO, CA | ACCOUNTING SERVICES | $158,244 |
2017 · 4 contractors · $943K
| Name | Location | Service | Paid |
|---|---|---|---|
| BOZICEVIC FIELD AND FRANCIS | EAST PALO ALTO, CA | LEGAL SERVICES | $304,755 |
| ELLUCIAN COMPANY LP | MALVERN, PA | CONSULTING SERVICES | $262,983 |
| DLA PIPER LLP (US) | BALTIMORE, MD | LEGAL SERVICES | $245,001 |
| MOSS ADAMS LLP | SAN DIEGO, CA | ACCOUNTING SERVICES | $130,313 |
2016 · 5 contractors · $1.2M
| Name | Location | Service | Paid |
|---|---|---|---|
| Ellucian Company LP | Malvern, PA | Consulting services | $333,931 |
| Bozicevic Field and Francis | East Palo Alto, CA | legal services | $301,027 |
| DLA Piper LLP (US) | Baltimore, MD | Legal services | $296,996 |
| Moss Adams LLP | San Diego, CA | Accounting Services | $162,930 |
| Littler Mendelson PC | San Francisco, CA | Legal services | $143,192 |
2015 · 5 contractors · $1.6M
| Name | Location | Service | Paid |
|---|---|---|---|
| DLA Piper LLP (US) | Baltimore, MD | Legal services | $386,252 |
| Bozicevic Field and Francis | East Palo Alto, CA | legal services | $352,600 |
| Ellucian Company LP | Malvern, PA | Consulting services | $347,549 |
| Profectus Pharma Consulting | San Jose, CA | consulting services | $272,010 |
| Littler Mendelson PC | San Francisco, CA | Legal services | $197,337 |
2014 · 5 contractors · $1.1M
| Name | Location | Service | Paid |
|---|---|---|---|
| BOZICEVIC FIELD AND FRANCIS | EAST PALO ALTO, CA | LEGAL SERVICES | $276,349 |
| PROFECTUS PHARMA CONSULTING | SAN JOSE, CA | CONSULTING SERVICES | $248,075 |
| BARNEY & BARNEY LLC | SAN DIEGO, CA | INSURANCE SERVICES | $220,538 |
| MOSS - ADAMS LLP | SAN DIEGO, CA | ACCOUNTING SERVICES | $189,465 |
| ISIS SERVICES | TAMPA, FL | LAB TESTING SERVICES | $135,119 |
2013 · 5 contractors · $995K
| Name | Location | Service | Paid |
|---|---|---|---|
| BOZICEVIC FIELD & FRANCIS | LEGAL SERVICES | $279,310 | |
| ISIS SERVICES | LAB TESTING SERVICES | $201,268 | |
| HOGAN LOVELLS US LLP | LEGAL SERVICES | $194,749 | |
| PROFECTUS PHARMA CONSULTING | CONSULTING SERVICES | $191,376 | |
| MOSS ADAMS LLP | ACCOUNTING SERVICES | $127,905 |
2012 · 3 contractors · $682K
| Name | Location | Service | Paid |
|---|---|---|---|
| BOZICEVIC FIELD & FRANCIS | EAST PALO ALTO, CA | LEGAL SERVICES | $400,782 |
| HOGAN LOVELLS US LLP | PALO ALTO, CA | LEGAL SERVICES | $156,520 |
| MOSS-ADAMS LLP | SAN DIEGO, CA | ACCOUNTING SERVICES | $124,975 |
2011 · 5 contractors · $956K
| Name | Location | Service | Paid |
|---|---|---|---|
| BOZICEVIC FIELD & FRANCIS | SAN FRANCISCO, CA | LEGAL SERVICES | $317,250 |
| BRAZER COMMUNICATIONS | MILL VALLEY, CA | PUBLIC RELATIONS SERVICES | $269,848 |
| MOSS-ADAMS LLP | SAN DIEGO, CA | ACCOUNTING SERVICES | $135,270 |
| LOEB & LOEB LLP | LOS ANGELES, CA | LEGAL SERVICES | $123,325 |
| CARLSON BECK LLC | SAN FRANCISCO, CA | RECRUITING SERVICES | $110,388 |
2010 · 5 contractors · $1.2M
| Name | Location | Service | Paid |
|---|---|---|---|
| THE BANCHERO LAW FIRM | SAN FRANCISCO, CA | LEGAL SERVICES | $411,000 |
| BOZICEVIC FIELD & FRANCIS | SAN FRANCISCO, CA | LEGAL SERVICES | $299,846 |
| SBF CONSULTING | SAN FRANCISCO, CA | INTELLECTUAL PROPERTY SERVICES | $187,213 |
| BRUCE SPAULDING | SAN FRANCISCO, CA | BUSINESS DEVELOPMENT | $154,000 |
| MOSS-ADAMS LLP | SAN DIEGO, CA | ACCOUNTING SERVICES | $110,000 |
Who gave
Contributor names are not public for this form type.
Public charities filing Form 990 or 990-EZ report large donors on Schedule B, but the IRS withholds their names and addresses from public copies. Private foundations (990-PF) are different: their contributors are public.
Finances
Newest first. Each filing: its name on one row, its figures on the row beneath. Greyed filings are superseded by a later return for the same period and are left out everywhere else on this page.
| Revenue | Expenses | Assets | Net assets | Contributions | Program revenue | Officer pay | Employees | Volunteers |
|---|---|---|---|---|---|---|---|---|
| 2024 · Form 990 | ||||||||
| $119,155,911 | $144,808,821 | $371,967,489 | $167,595,974 | $16,072,228 | $94,130,588 | $7,145,674 | 593 | 90 |
| 2023 · Form 990 | ||||||||
| $119,208,526 | $127,669,032 | $365,291,245 | $172,425,834 | $20,222,638 | $85,513,618 | $7,436,666 | 581 | 126 |
| 2022 · Form 990 | ||||||||
| $144,774,821 | $118,956,646 | $358,330,486 | $167,643,324 | $55,156,655 | $76,577,087 | $7,226,936 | 579 | 110 |
| 2021 · Form 990 | ||||||||
| $143,049,979 | $103,017,350 | $367,466,101 | $176,125,318 | $70,616,690 | $65,809,447 | $6,644,310 | 530 | 85 |
| 2020 · Form 990 | ||||||||
| $84,274,665 | $93,512,759 | $318,407,379 | $120,832,260 | $8,871,876 | $58,349,338 | $6,080,794 | 473 | 40 |
| 2019 · Form 990 | ||||||||
| $62,831,350 | $82,269,244 | $314,172,354 | $124,840,825 | $12,763,261 | $52,102,454 | $4,575,540 | 485 | 100 |
| 2018 · Form 990 | ||||||||
| $86,315,298 | $83,576,420 | $257,431,204 | $131,097,832 | $23,872,739 | $57,064,176 | $4,051,283 | 490 | 110 |
| 2017 · Form 990 | ||||||||
| $84,597,148 | $83,899,382 | $270,741,190 | $132,603,348 | $19,722,592 | $60,707,205 | $4,479,721 | 487 | 90 |
| 2016 · Form 990 | ||||||||
| $67,385,094 | $84,543,592 | $259,825,160 | $119,024,862 | $802,707 | $62,077,407 | $4,366,942 | 482 | 87 |
| 2015 · Form 990 | ||||||||
| $66,831,559 | $82,885,330 | $265,965,861 | $132,056,072 | $4,780,090 | $56,181,372 | $4,430,058 | 503 | 85 |
| 2014 · Form 990 | ||||||||
| $86,317,449 | $81,593,162 | $287,366,861 | $154,449,352 | $11,855,653 | $54,795,933 | $4,214,326 | 508 | 85 |
| 2013 · Form 990 | ||||||||
| $80,164,886 | $78,842,979 | $292,117,051 | $154,940,589 | $2,914,056 | $55,917,786 | $4,113,157 | 534 | 85 |
| 2012 · Form 990 | ||||||||
| $88,112,434 | $82,921,017 | $311,301,015 | $155,978,606 | $10,796,559 | $60,457,987 | $4,000,232 | 485 | 85 |
| 2011 · Form 990 | ||||||||
| $73,212,869 | $86,638,584 | $319,515,917 | $152,935,255 | $6,305,182 | $61,538,786 | $4,049,403 | 474 | 85 |
| 2010 · Form 990 | ||||||||
| $73,764,573 | $78,754,762 | $338,133,259 | $174,133,130 | $7,266,486 | $58,770,072 | $2,966,115 | 399 | 85 |
Connected to
Organizations that list some of the same people on their returns (officers, directors, key employees on this organization’s latest return), and related organizations it lists on Schedule R.
- GLADSTONE FOUNDATION San Francisco, CA · 2 people in common (Deepak Srivastava, Nicholas J Simon) · related organization (Schedule R)
Funders of this organization
99 grantors reported grants to this organization, $233,086,089 in all, tax years 2009 to 2025; the 25 largest shown (all 99). Exact: the grantor wrote this organization's EIN. Fuzzy: the grantor wrote only a name (foundations' 990-PF has no EIN field), matched to the same or a near-identical name in the same state; the name as filed is shown. From the latest return for each grantor and year, so amended returns aren't counted twice. CSV
| Grantor | Type | Match | Years given | Grants | Total | Latest year | Latest year's amount | Grants |
|---|---|---|---|---|---|---|---|---|
| GLADSTONE FOUNDATION | Public charity | Exact | 2018-2024 | 7 | $74,808,078 | 2024 | $7,214,906 | show |
| LK WHITTIER FOUNDATION | Private foundation | Fuzzy filed as “J DAVID GLADSTONE INSTITUTE” | 2020-2022 | 3 | $33,000,000 | 2022 | $27,000,000 | show |
| DONOR ADVISED CHARITABLE GIVING | DAF sponsor | Exact | 2014-2024 | 11 | $13,429,000 | 2024 | $2,618,250 | show |
| WILLIAM K BOWES JR FOUNDATION | Private foundation | Fuzzy filed as “J DAVID GLADSTONE INSTITUTES” | 2020-2024 | 5 | $10,000,000 | 2024 | $2,000,000 | show |
| PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY | Public charity | Exact | 2021-2025 | 5 | $8,104,586 | 2025 | $175,000 | show |
| AMERICAN HEART ASSOCIATION INC | Public charity | Exact | 2010-2024 | 15 | $7,915,194 | 2024 | $314,960 | show |
| MARIN COMMUNITY FOUNDATION | DAF sponsor | Exact | 2012, 2016-2024 | 10 | $5,780,250 | 2024 | $2,047,500 | show |
| MICHAEL J FOX FOUNDATION FOR PARKINSONS RESEARCH | Public charity | Exact | 2013, 2015-2019 | 6 | $5,263,468 | 2019 | $267,439 | show |
| ADDITIONAL VENTURES FOUNDATION | Private foundation | Fuzzy filed as “J DAVID GLADSTONE INSTITUTES”, “THE J DAVID GLADSTONE INSTITUTES” | 2019, 2021-2024 | 8 | $5,257,045 | 2024 | $1,345,098 | show |
| GORDON E AND BETTY I MOORE FOUNDATION | Private foundation | Fuzzy filed as “J David Gladstone Institutes”, “J DAVID GLADSTONE INSTITUTES” | 2011-2014, 2022-2023 | 6 | $5,254,003 | 2023 | $2,036,651 | show |
| THE MILKEN INSTITUTE | Public charity | Exact | 2024 | 1 | $4,843,866 | 2024 | $4,843,866 | show |
| SILICON VALLEY COMMUNITY FOUNDATION | DAF sponsor | Exact | 2011, 2013-2015, 2017, 2020, 2023-2024 | 8 | $4,518,650 | 2024 | $3,263,650 | show |
| NORTHWESTERN UNIVERSITY | DAF sponsor | Exact | 2018-2024 | 7 | $3,818,213 | 2024 | $567,087 | show |
| AMYOTROPHIC LATERAL SCLEROSIS ASSN | Public charity | Exact | 2011-2015, 2017-2019, 2022-2023 | 12 | $3,114,722 | 2023 | $50,000 | show |
| W M KECK FOUNDATION | Private foundation | Fuzzy filed as “THE J DAVID GLADSTONE INSTITUTES” | 2023 | 2 | $2,600,000 | 2023 | $2,600,000 | show |
| ESB CHARITABLE FOUNDATION | Private foundation | Fuzzy filed as “J David Gladstone Institutes”, “J DAVID GLADSTONE INSTITUTES” | 2014-2015 | 3 | $2,600,000 | 2015 | $1,200,000 | show |
| FIDELITY INVESTMENTS CHARITABLE GIFT FUND | DAF sponsor | Exact | 2017-2019 | 3 | $2,573,950 | 2019 | $39,550 | show |
| FARMER FAMILY FOUNDATION | Private foundation | Fuzzy filed as “J DAVID GLADSTONE INSTITUTES” | 2021-2024 | 4 | $2,350,000 | 2024 | $350,000 | show |
| KORET FOUNDATION | Private foundation | Fuzzy filed as “J DAVID GLADSTONE INSTITUTES” | 2019-2020, 2022-2024 | 5 | $2,200,000 | 2024 | $300,000 | show |
| NATIONAL PHILANTHROPIC TR | DAF sponsor | Exact | 2014, 2019-2024 | 7 | $2,096,153 | 2024 | $45,000 | show |
| WASHINGTON UNIVERSITY | DAF sponsor | Exact | 2014-2016, 2019-2024 | 9 | $2,075,517 | 2024 | $298,689 | show |
| JAMES B PENDLETON IRRV CHARIT TR 091692 | Private foundation | Fuzzy filed as “J DAVID GLADSTONE INSTITUTES”, “THE J DAVID GLADSTONE INSTITUTES” | 2018-2025 | 8 | $2,025,000 | 2025 | $275,000 | show |
| TRUSTEES OF COLUMBIA UNIVERSITY | DAF sponsor | Exact | 2013-2014, 2017-2024 | 10 | $1,947,348 | 2024 | $95,790 | show |
| THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | DAF sponsor | Exact | 2016-2017, 2019-2024 | 10 | $1,659,000 | 2024 | $100,000 | show |
| SCRIPPS RESEARCH INSTITUTE | Public charity | Exact | 2020-2024 | 5 | $1,610,427 | 2024 | $327,905 | show |
Nearby + Similar BETA
Organizations like this one: what they do and who they are linked to
Same category: NTEE code and revenue
Ranked without any AI: same NTEE code first, then the same NTEE group; then revenue within 2x, 5x or 10x; then the same state; then similar name and mission text. Same state only · More (100)
| Organization | State | NTEE | Latest revenue | Latest expenses | Top-paid title | Top pay | Why similar |
|---|---|---|---|---|---|---|---|
| LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL | CA | H90 | $94,550,669 | $106,850,446 | INTERIM CEO | $925,655 | Same NTEE code H90, revenue within 2x, same state |
| BAYLOR RESEARCH INSTITUTE | TX | H90 | $89,491,341 | $85,910,172 | Trustee | $2,977,455 | Same NTEE code H90, revenue within 2x |
| THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH | NY | H90 | $163,308,471 | $163,279,325 | EVP & CFO | $1,990,193 | Same NTEE code H90, revenue within 2x |
| TRANSLATIONAL GENOMICS RESEARCH INSTITUTE | AZ | H90 | $75,913,310 | $86,279,860 | BD & VICE CHRM/COH CEO & PRES. | $7,115,857 | Same NTEE code H90, revenue within 2x |
| THE MEDICAL UNIVERSITY OF SOUTH CAROLINA FOUNDATION | SC | H90 | $136,664,063 | $81,004,152 | CHIEF EXECUTIVE OFFICER | $635,452 | Same NTEE code H90, revenue within 2x |
| HENNEPIN HEALTHCARE RESEARCH INSTITUTE | MN | H90 | $54,717,221 | $53,504,403 | DIRECTOR/PHYSICIAN (UNTIL 6/24) | $660,695 | Same NTEE code H90, revenue within 5x |
| SPORTS MEDICINE RESEARCH AND TESTING LABORATORY | UT | H90 | $24,588,184 | $16,194,140 | PRESIDENT/LAB DIRECTOR | $622,114 | Same NTEE code H90, revenue within 5x |
| VETERANS MEDICAL RESEARCH FOUNDATION OF SD | CA | H90 | $16,030,812 | $16,560,898 | EXECUTIVE DIRECTOR/CEO | $405,278 | Same NTEE code H90, revenue within 10x, same state |
| WILLIAM K WARREN MEDICAL RESEARCH CENTER INC | OK | H90 | $16,183,718 | $1,805,546 | DIRECTOR | $508,503 | Same NTEE code H90, revenue within 10x |
| MONELL CHEMICAL SENSES CENTER | PA | H90 | $20,726,758 | $20,366,058 | Exec Dir President | $360,927 | Same NTEE code H90, revenue within 10x |
| REGENSTRIEF FOUNDATION INC | IN | H90 | $14,893,999 | $11,220,711 | PRESIDENT & DIRECTOR | $221,759 | Same NTEE code H90, revenue within 10x |
| HUNTINGTON MEDICAL RESEARCH INSTITUTES | CA | H90 | $7,051,359 | $13,260,671 | PRESIDENT AND CEO | $515,480 | Same NTEE code H90, revenue differs more than 10x, same state |
| ALLES INSTITUTE FOR MEDICAL RESEARCH | CA | H90 | $1,152,425 | $474,710 | Secretary | $811 | Same NTEE code H90, revenue differs more than 10x, same state |
| VACCINE RESEARCH INSTITUTE OF SAN DIEGO | CA | H90 | $664,888 | $625,296 | SR SCIENTIST | $98,700 | Same NTEE code H90, revenue differs more than 10x, same state |
| GLOBAL INSTITUTE FOR TIBETAN MEDICINE | CA | H90 | $72,180 | $72,427 | Board Chair and Medical Director | $25,700 | Same NTEE code H90, revenue differs more than 10x, same state |
| THE HOUSE INSTITUTE FOUNDATION | CA | H90 | $2,572,090 | $2,552,536 | EXECUTIVE DIRECTOR | $233,701 | Same NTEE code H90, revenue differs more than 10x, same state |
| INSTITUTE OF REGENERATIVE AND CELLULAR MEDICINE | CA | H90 | $82,464 | $98,225 | SECRETARY | $13,000 | Same NTEE code H90, revenue differs more than 10x, same state |
| SUI HEALTH - SERVING US INDIVIDUALL Y | CA | H90 | $220,000 | $79,357 | Treasurer and Director | $0 | Same NTEE code H90, revenue differs more than 10x, same state |
| INSTITUTE FOR SEXUAL MEDICINE INC | CA | H90 | $50,207 | $38,128 | PRESIDENT | $0 | Same NTEE code H90, revenue differs more than 10x, same state |
| CENTER FOR GENOMIC PATHOLOGY | CA | H90 | $189,618 | $165,702 | Chief Administrative Officer | $15,754 | Same NTEE code H90, revenue differs more than 10x, same state |
| INTERNATIONAL ANESTHESIA RESEARCH SOCIETY | CA | H90 | $6,860,258 | $5,893,713 | EXECUTIVE DIRECTOR (UNTIL AUGUST) | $330,258 | Same NTEE code H90, revenue differs more than 10x, same state |
| MIRAKIND | CA | H90 | $77,504 | $123,210 | ADVISOR | $0 | Same NTEE code H90, revenue differs more than 10x, same state |
| AMERICAN LIMB PRESERVATION SOCIETY | CA | H90 | $846,208 | $877,685 | CEO | $297,207 | Same NTEE code H90, revenue differs more than 10x, same state |
| CHAN SOON-SHIONG NANTHEALTH FOUNDATION | CA | H90 | $64,855 | $743,382 | DIRECTOR OF GOVT. RELATIONS | $331,008 | Same NTEE code H90, revenue differs more than 10x, same state |
| CALIFORNIA INSTITUTE OF COMPUTERASSISTED SURGERY INC | CA | H90 | $3,562 | $93,824 | President | $0 | Same NTEE code H90, revenue differs more than 10x, same state |
Who funds organizations like this
Grantors that funded the 100 most similar organizations. Ranked by total given to them. Foundations (990-PF) and donor-advised fund sponsors only. Same matching as Funders above (by EIN, or by name for foundations).
The full list · all similar organizations
Where the money went
Every expense line on each return, biggest first: Form 990 Part IX (with its program, management and fundraising columns), 990-EZ Part I, or 990-PF Part I. Event marks lines the organization itself describes as events. “Events” in each summary adds those lines, conferences and meetings, and the direct costs of fundraising events. Unusual is not the same as improper. Many of these patterns have ordinary explanations. Check the filing.
2024 · Form 990 · $144,808,821 spent · pay $75,367,376 · grants $0 · events $0
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $49,035,201 | $38,371,002 | $9,456,414 | $1,207,785 | 33.9% | |
| Fees: other services | $22,062,301 | $21,082,185 | $565,697 | $414,419 | 15.2% | |
| Office expenses | $14,532,180 | $14,490,600 | - | $41,580 | 10.0% | |
| Other employee benefits | $11,150,383 | $8,589,033 | $2,091,215 | $470,135 | 7.7% | |
| Occupancy | $7,565,811 | $6,885,246 | $679,840 | $725 | 5.2% | |
| Depreciation and depletion | $7,527,183 | $6,758,348 | $768,835 | - | 5.2% | |
| Pay: officers, directors, trustees, key employees | $7,145,674 | $5,598,983 | $1,375,348 | $171,343 | 4.9% | |
| Interest | $6,983,420 | $6,023,788 | $959,632 | - | 4.8% | |
| Pension plan contributions | $4,471,280 | $3,621,906 | $849,374 | - | 3.1% | |
| Other (as described) | ANIMALS | $3,760,378 | $3,760,378 | - | - | 2.6% |
| Payroll taxes | $3,564,838 | $2,887,657 | $677,181 | - | 2.5% | |
| Information technology | $2,056,888 | $2,051,861 | - | $5,027 | 1.4% | |
| Travel | $1,304,398 | $1,285,457 | $6,314 | $12,627 | 0.9% | |
| Insurance | $1,134,942 | $863,641 | $271,301 | - | 0.8% | |
| Fees: legal | $995,326 | $635,658 | $359,668 | - | 0.7% | |
| Fees: investment management | $476,219 | - | $476,219 | - | 0.3% | |
| All other expenses | $320,223 | $305,174 | $37 | $15,012 | 0.2% | |
| Advertising and promotion | $267,928 | $253,280 | $626 | $14,022 | 0.2% | |
| Fees: accounting | $256,249 | - | $256,249 | - | 0.2% | |
| Royalties | $197,999 | $197,999 | - | - | 0.1% | |
| Total | $144,808,821 | 100% |
2023 · Form 990 · $127,669,032 spent · pay $65,914,250 · grants $0 · events $0
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $43,009,522 | $32,871,707 | $9,069,149 | $1,068,666 | 33.7% | |
| Fees: other services | $19,487,550 | $18,386,065 | $751,614 | $349,871 | 15.3% | |
| Office expenses | $12,020,497 | $11,999,017 | $190 | $21,290 | 9.4% | |
| Other employee benefits | $8,802,438 | $6,387,967 | $1,999,946 | $414,525 | 6.9% | |
| Pay: officers, directors, trustees, key employees | $7,436,666 | $5,673,400 | $1,582,363 | $180,903 | 5.8% | |
| Depreciation and depletion | $6,999,123 | $6,200,780 | $798,343 | - | 5.5% | |
| Interest | $6,749,567 | $5,987,385 | $762,182 | - | 5.3% | |
| Occupancy | $6,744,036 | $6,047,906 | $695,730 | $400 | 5.3% | |
| Pension plan contributions | $3,417,002 | $2,625,770 | $791,232 | - | 2.7% | |
| Other (as described) | ANIMALS | $3,407,324 | $3,407,324 | - | - | 2.7% |
| Payroll taxes | $3,248,622 | $2,496,375 | $752,247 | - | 2.5% | |
| Travel | $1,540,516 | $1,454,983 | $81,639 | $3,894 | 1.2% | |
| Information technology | $1,496,382 | $1,478,307 | - | $18,075 | 1.2% | |
| Insurance | $1,256,380 | $941,163 | $315,217 | - | 1.0% | |
| Fees: legal | $702,222 | $531,054 | $171,168 | - | 0.6% | |
| Fees: investment management | $427,463 | - | $427,463 | - | 0.3% | |
| Advertising and promotion | $338,640 | $335,515 | $209 | $2,916 | 0.3% | |
| All other expenses | $247,134 | $246,089 | $242 | $803 | 0.2% | |
| Fees: accounting | $236,114 | - | $236,114 | - | 0.2% | |
| Royalties | $101,834 | $101,834 | - | - | 0.1% | |
| Total | $127,669,032 | 100% |
2022 · Form 990 · $118,956,646 spent · pay $61,067,877 · grants $0 · events $0
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $38,878,225 | $29,655,356 | $8,169,341 | $1,053,528 | 32.7% | |
| Fees: other services | $17,265,949 | $16,067,493 | $1,154,929 | $43,527 | 14.5% | |
| Office expenses | $11,599,432 | $11,579,719 | $509 | $19,204 | 9.8% | |
| Other employee benefits | $8,701,716 | $6,448,220 | $1,834,478 | $419,018 | 7.3% | |
| Pay: officers, directors, trustees, key employees | $7,226,936 | $5,515,318 | $1,520,579 | $191,039 | 6.1% | |
| Interest | $6,882,846 | $6,044,838 | $838,008 | - | 5.8% | |
| Occupancy | $6,792,261 | $6,107,213 | $685,048 | - | 5.7% | |
| Depreciation and depletion | $6,680,400 | $5,919,070 | $761,330 | - | 5.6% | |
| Pension plan contributions | $3,351,236 | $2,631,725 | $719,511 | - | 2.8% | |
| Other (as described) | ANIMALS | $3,264,607 | $3,264,607 | - | - | 2.7% |
| Payroll taxes | $2,909,764 | $2,285,089 | $624,675 | - | 2.4% | |
| Insurance | $1,448,271 | $1,104,291 | $343,980 | - | 1.2% | |
| Information technology | $1,293,915 | $1,284,202 | $229 | $9,484 | 1.1% | |
| Travel | $1,065,920 | $1,052,095 | $11,320 | $2,505 | 0.9% | |
| Fees: legal | $780,717 | $735,522 | $45,195 | - | 0.7% | |
| Fees: investment management | $388,890 | - | $388,890 | - | 0.3% | |
| Fees: accounting | $219,845 | - | $219,845 | - | 0.2% | |
| All other expenses | $98,430 | $98,012 | - | $418 | 0.1% | |
| Advertising and promotion | $77,286 | $77,286 | - | - | 0.1% | |
| Royalties | $30,000 | $30,000 | - | - | 0.0% | |
| Total | $118,956,646 | 100% |
2021 · Form 990 · $103,017,350 spent · pay $55,555,884 · grants $0 · events $0
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $35,576,413 | $27,889,860 | $6,838,081 | $848,472 | 34.5% | |
| Fees: other services | $11,768,805 | $11,045,715 | $669,044 | $54,046 | 11.4% | |
| Office expenses | $9,819,175 | $9,783,630 | $24,011 | $11,534 | 9.5% | |
| Other employee benefits | $7,718,275 | $5,853,606 | $1,526,862 | $337,807 | 7.5% | |
| Interest | $6,958,160 | $6,151,645 | $806,515 | - | 6.8% | |
| Pay: officers, directors, trustees, key employees | $6,644,310 | $5,207,970 | $1,281,949 | $154,391 | 6.4% | |
| Depreciation and depletion | $6,501,017 | $5,815,714 | $685,303 | - | 6.3% | |
| Occupancy | $5,455,429 | $4,954,657 | $500,772 | - | 5.3% | |
| Other (as described) | ANIMALS | $3,072,019 | $3,072,019 | - | - | 3.0% |
| Pension plan contributions | $2,936,814 | $2,345,041 | $591,773 | - | 2.9% | |
| Payroll taxes | $2,680,072 | $2,140,037 | $540,035 | - | 2.6% | |
| Insurance | $1,431,130 | $1,213,390 | $217,740 | - | 1.4% | |
| Information technology | $983,050 | $982,423 | - | $627 | 1.0% | |
| Fees: legal | $573,753 | $553,196 | $20,557 | - | 0.6% | |
| Fees: investment management | $411,200 | - | $411,200 | - | 0.4% | |
| Travel | $235,148 | $229,659 | $5,172 | $317 | 0.2% | |
| Fees: accounting | $222,580 | - | $222,580 | - | 0.2% | |
| Royalties | $30,000 | $30,000 | - | - | 0.0% | |
| Total | $103,017,350 | 100% |
2020 · Form 990 · $93,512,759 spent · pay $49,154,685 · grants $0 · events $0
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $32,172,627 | $25,063,958 | $6,321,089 | $787,580 | 34.4% | |
| Fees: other services | $11,021,921 | $10,324,690 | $668,397 | $28,834 | 11.8% | |
| Office expenses | $8,458,957 | $8,456,945 | $240 | $1,772 | 9.0% | |
| Interest | $6,941,278 | $6,230,781 | $710,497 | - | 7.4% | |
| Depreciation and depletion | $6,347,196 | $5,681,248 | $665,948 | - | 6.8% | |
| Pay: officers, directors, trustees, key employees | $6,080,794 | $4,734,828 | $1,205,133 | $140,833 | 6.5% | |
| Other employee benefits | $5,670,875 | $4,084,049 | $1,281,166 | $305,660 | 6.1% | |
| Occupancy | $4,764,350 | $4,337,188 | $427,162 | - | 5.1% | |
| Other (as described) | ANIMALS | $2,982,945 | $2,982,945 | $0 | $0 | 3.2% |
| Pension plan contributions | $2,810,145 | $2,168,730 | $641,415 | - | 3.0% | |
| Payroll taxes | $2,420,244 | $1,867,824 | $552,420 | - | 2.6% | |
| Insurance | $1,204,639 | $995,371 | $209,268 | - | 1.3% | |
| Information technology | $670,089 | $664,684 | - | $5,405 | 0.7% | |
| Fees: legal | $539,276 | $457,802 | $78,030 | $3,444 | 0.6% | |
| Fees: investment management | $408,243 | - | $408,243 | - | 0.4% | |
| Travel | $338,058 | $332,030 | $4,696 | $1,332 | 0.4% | |
| Other (as described) | TELEPHONE & COMMUNICATI | $251,621 | $247,655 | $2,534 | $1,432 | 0.3% |
| Fees: accounting | $206,512 | - | $206,512 | - | 0.2% | |
| Royalties | $136,196 | $136,196 | - | - | 0.1% | |
| Other (as described) | PRINTING & PUBLICATION | $83,454 | $83,034 | $0 | $420 | 0.1% |
| All other expenses | $1,914 | - | $1,742 | $172 | 0.0% | |
| Other (as described) | POSTAGE & DELIVERY | $1,425 | $1,425 | $0 | $0 | 0.0% |
| Total | $93,512,759 | 100% |
2019 · Form 990 · $82,269,244 spent · pay $45,793,947 · grants $0 · events $0
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $30,685,679 | $23,231,840 | $6,728,189 | $725,650 | 37.3% | |
| Office expenses | $7,112,541 | $7,111,592 | $47 | $902 | 8.6% | |
| Fees: other services | $6,627,009 | $6,356,789 | $227,464 | $42,756 | 8.1% | |
| Depreciation and depletion | $6,035,302 | $5,393,422 | $641,880 | - | 7.3% | |
| Other employee benefits | $5,586,781 | $4,116,313 | $1,248,027 | $222,441 | 6.8% | |
| Interest | $5,296,594 | $4,591,386 | $705,208 | - | 6.4% | |
| Pay: officers, directors, trustees, key employees | $4,575,540 | $3,451,027 | $1,124,513 | - | 5.6% | |
| Occupancy | $3,004,000 | $2,687,635 | $316,365 | - | 3.7% | |
| Pension plan contributions | $2,710,250 | $2,140,414 | $569,836 | - | 3.3% | |
| Other (as described) | ANIMALS | $2,671,296 | $2,671,296 | - | - | 3.2% |
| Payroll taxes | $2,235,697 | $1,725,632 | $510,065 | - | 2.7% | |
| Travel | $1,659,557 | $1,608,462 | $25,918 | $25,177 | 2.0% | |
| Insurance | $873,652 | $685,654 | $187,998 | - | 1.1% | |
| Information technology | $761,780 | $754,516 | $542 | $6,722 | 0.9% | |
| Other (as described) | PRINTING & PUBLICATION | $571,772 | $559,747 | $3,338 | $8,687 | 0.7% |
| Fees: legal | $466,630 | $412,910 | $53,720 | - | 0.6% | |
| All other expenses | $292,926 | $287,617 | $5,309 | - | 0.4% | |
| Fees: investment management | $267,372 | - | $267,372 | - | 0.3% | |
| Other (as described) | TELEPHONE & COMMUNICATI | $247,957 | $241,919 | $3,235 | $2,803 | 0.3% |
| Royalties | $223,766 | $223,766 | - | - | 0.3% | |
| Fees: accounting | $186,075 | - | $186,075 | - | 0.2% | |
| Other (as described) | POSTAGE & DELIVERY | $177,068 | $176,039 | $103 | $926 | 0.2% |
| Total | $82,269,244 | 100% |
2018 · Form 990 · $83,576,420 spent · pay $41,854,306 · grants $0 · events $0
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $27,769,596 | $21,266,516 | $6,087,692 | $415,388 | 33.2% | |
| Fees: other services | $10,083,503 | $8,614,974 | $1,343,899 | $124,630 | 12.1% | |
| Office expenses | $8,113,664 | $8,112,007 | $1,367 | $290 | 9.7% | |
| Depreciation and depletion | $6,359,801 | $5,664,198 | $695,603 | - | 7.6% | |
| Interest | $5,551,029 | $4,705,295 | $845,734 | - | 6.6% | |
| Other employee benefits | $5,520,995 | $4,236,891 | $1,166,228 | $117,876 | 6.6% | |
| Pay: officers, directors, trustees, key employees | $4,051,283 | $3,086,361 | $964,922 | - | 4.8% | |
| Occupancy | $2,908,937 | $2,590,792 | $318,145 | - | 3.5% | |
| Other (as described) | ANIMALS | $2,773,017 | $2,773,017 | - | - | 3.3% |
| Pension plan contributions | $2,408,651 | $1,941,606 | $467,045 | - | 2.9% | |
| Payroll taxes | $2,103,781 | $1,657,432 | $446,349 | - | 2.5% | |
| Travel | $1,508,768 | $1,455,944 | $21,968 | $30,856 | 1.8% | |
| Fees: legal | $916,338 | $692,812 | $223,526 | - | 1.1% | |
| Insurance | $732,278 | $569,748 | $162,530 | - | 0.9% | |
| Information technology | $647,181 | $643,309 | $130 | $3,742 | 0.8% | |
| All other expenses | $594,796 | $593,668 | $327 | $801 | 0.7% | |
| Royalties | $485,000 | $485,000 | - | - | 0.6% | |
| Other (as described) | TELEPHONE & COMMUNICATI | $293,391 | $289,274 | $2,985 | $1,132 | 0.4% |
| Fees: investment management | $282,415 | - | $282,415 | - | 0.3% | |
| Other (as described) | POSTAGE & DELIVERY | $180,168 | $179,559 | $51 | $558 | 0.2% |
| Fees: accounting | $170,004 | - | $170,004 | - | 0.2% | |
| Other (as described) | PRINTING & PUBLICATION | $121,824 | $115,195 | - | $6,629 | 0.1% |
| Total | $83,576,420 | 100% |
2017 · Form 990 · $83,899,382 spent · pay $43,064,747 · grants $0 · events $0
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $28,950,742 | $22,784,287 | $5,585,048 | $581,407 | 34.5% | |
| Fees: other services | $9,403,352 | $8,644,284 | $707,118 | $51,950 | 11.2% | |
| Office expenses | $8,267,166 | $8,264,016 | $81 | $3,069 | 9.9% | |
| Depreciation and depletion | $6,518,874 | $5,854,014 | $664,860 | - | 7.8% | |
| Interest | $5,532,677 | $4,883,894 | $648,783 | - | 6.6% | |
| Other employee benefits | $4,966,240 | $3,823,302 | $1,020,993 | $121,945 | 5.9% | |
| Pay: officers, directors, trustees, key employees | $4,479,721 | $3,594,317 | $885,404 | - | 5.3% | |
| Occupancy | $3,031,738 | $2,722,538 | $309,200 | - | 3.6% | |
| Other (as described) | ANIMALS | $2,799,022 | $2,799,022 | - | - | 3.3% |
| Pension plan contributions | $2,512,950 | $1,996,039 | $516,911 | - | 3.0% | |
| Payroll taxes | $2,155,094 | $1,711,794 | $443,300 | - | 2.6% | |
| Travel | $1,259,290 | $1,227,125 | $19,283 | $12,882 | 1.5% | |
| All other expenses | $814,920 | $814,096 | $342 | $482 | 1.0% | |
| Insurance | $763,220 | $595,161 | $168,059 | - | 0.9% | |
| Fees: legal | $746,318 | $628,351 | $117,967 | - | 0.9% | |
| Information technology | $614,151 | $599,677 | - | $14,474 | 0.7% | |
| Other (as described) | TELEPHONE & COMMUNICATI | $344,770 | $342,655 | $1,790 | $325 | 0.4% |
| Fees: investment management | $269,551 | - | $269,551 | - | 0.3% | |
| Other (as described) | POSTAGE & DELIVERY | $187,813 | $186,965 | $71 | $777 | 0.2% |
| Fees: accounting | $153,013 | $21,000 | $132,013 | - | 0.2% | |
| Other (as described) | PRINTING & PUBLICATION | $113,277 | $110,934 | - | $2,343 | 0.1% |
| Royalties | $15,483 | $15,483 | - | - | 0.0% | |
| Total | $83,899,382 | 100% |
2016 · Form 990 · $84,543,592 spent · pay $42,533,560 · grants $0 · events $0
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $28,756,135 | $23,958,196 | $4,318,497 | $479,442 | 34.0% | |
| Fees: other services | $9,382,782 | $8,514,425 | $788,768 | $79,589 | 11.1% | |
| Office expenses | $8,150,362 | $8,146,844 | $482 | $3,036 | 9.6% | |
| Depreciation and depletion | $7,124,047 | $6,407,873 | $716,174 | - | 8.4% | |
| Interest | $5,775,549 | $4,979,610 | $795,939 | - | 6.8% | |
| Other employee benefits | $4,762,131 | $3,685,245 | $925,343 | $151,543 | 5.6% | |
| Pay: officers, directors, trustees, key employees | $4,366,942 | $2,462,317 | $1,904,625 | - | 5.2% | |
| Other (as described) | animals | $2,963,472 | $2,963,472 | - | - | 3.5% |
| Occupancy | $2,754,661 | $2,480,877 | $273,784 | - | 3.3% | |
| Pension plan contributions | $2,546,250 | $2,074,835 | $471,415 | - | 3.0% | |
| Payroll taxes | $2,102,102 | $1,680,215 | $421,887 | - | 2.5% | |
| Travel | $1,310,427 | $1,258,158 | $38,230 | $14,039 | 1.6% | |
| Fees: legal | $1,023,841 | $819,100 | $204,741 | - | 1.2% | |
| Insurance | $840,567 | $668,735 | $171,832 | - | 1.0% | |
| Information technology | $831,037 | $819,699 | - | $11,338 | 1.0% | |
| All other expenses | $722,948 | $716,434 | $5,870 | $644 | 0.9% | |
| Other (as described) | telephone & communicati | $288,522 | $279,341 | $6,963 | $2,218 | 0.3% |
| Fees: investment management | $254,952 | - | $254,952 | - | 0.3% | |
| Other (as described) | postage & delivery | $190,357 | $188,744 | $553 | $1,060 | 0.2% |
| Other (as described) | printing & publication | $176,570 | $151,091 | - | $25,479 | 0.2% |
| Fees: accounting | $167,560 | $20,500 | $147,060 | - | 0.2% | |
| Royalties | $52,378 | $52,378 | - | - | 0.1% | |
| Total | $84,543,592 | 100% |
2015 · Form 990 · $82,885,330 spent · pay $42,825,466 · grants $0 · events $0
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $28,777,175 | $23,418,352 | $4,653,276 | $705,547 | 34.7% | |
| Fees: other services | $8,563,712 | $7,893,952 | $456,978 | $212,782 | 10.3% | |
| Office expenses | $8,157,646 | $8,153,373 | $1,560 | $2,713 | 9.8% | |
| Depreciation and depletion | $6,962,180 | $6,061,162 | $901,018 | - | 8.4% | |
| Interest | $5,697,341 | $4,949,401 | $747,940 | - | 6.9% | |
| Other employee benefits | $4,886,363 | $3,731,418 | $946,107 | $208,838 | 5.9% | |
| Pay: officers, directors, trustees, key employees | $4,430,058 | $2,561,144 | $1,868,914 | - | 5.3% | |
| Other (as described) | animals | $3,187,651 | $3,187,651 | - | - | 3.8% |
| Pension plan contributions | $2,640,000 | $2,117,672 | $522,328 | - | 3.2% | |
| Occupancy | $2,456,781 | $2,160,920 | $295,861 | - | 3.0% | |
| Payroll taxes | $2,091,870 | $1,677,990 | $413,880 | - | 2.5% | |
| Travel | $1,304,125 | $1,244,456 | $34,909 | $24,760 | 1.6% | |
| Insurance | $978,285 | $781,188 | $197,097 | - | 1.2% | |
| Fees: legal | $843,614 | $602,848 | $240,766 | - | 1.0% | |
| Information technology | $573,120 | $568,965 | - | $4,155 | 0.7% | |
| Fees: investment management | $278,850 | - | $278,850 | - | 0.3% | |
| Other (as described) | telephone & communicati | $260,230 | $249,318 | $2,787 | $8,125 | 0.3% |
| Other (as described) | postage & delivery | $204,208 | $200,454 | $2,874 | $880 | 0.2% |
| Royalties | $200,000 | $200,000 | - | - | 0.2% | |
| Fees: accounting | $168,873 | $24,395 | $144,478 | - | 0.2% | |
| Other (as described) | printing & publication | $145,139 | $137,271 | $132 | $7,736 | 0.2% |
| All other expenses | $78,109 | $75,377 | $312 | $2,420 | 0.1% | |
| Total | $82,885,330 | 100% |
2014 · Form 990 · $81,593,162 spent · pay $40,910,459 · grants $0 · events $0
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $27,095,152 | $20,865,623 | $5,411,856 | $817,673 | 33.2% | |
| Fees: other services | $8,674,168 | $8,211,143 | $270,705 | $192,320 | 10.6% | |
| Office expenses | $8,057,605 | $8,050,015 | $1,934 | $5,656 | 9.9% | |
| Depreciation and depletion | $6,474,988 | $5,632,905 | $842,083 | - | 7.9% | |
| Interest | $5,732,387 | $5,020,415 | $711,972 | - | 7.0% | |
| Other employee benefits | $4,834,965 | $3,658,827 | $937,719 | $238,419 | 5.9% | |
| Pay: officers, directors, trustees, key employees | $4,214,326 | $3,485,426 | $728,900 | - | 5.2% | |
| Other (as described) | ANIMALS | $3,491,062 | $3,491,062 | - | - | 4.3% |
| Pension plan contributions | $2,760,000 | $2,265,819 | $494,181 | - | 3.4% | |
| Occupancy | $2,602,051 | $2,300,443 | $301,308 | $300 | 3.2% | |
| Payroll taxes | $2,006,016 | $1,646,837 | $359,179 | - | 2.5% | |
| Travel | $1,202,518 | $1,148,610 | $32,618 | $21,290 | 1.5% | |
| Insurance | $973,819 | $775,225 | $198,594 | - | 1.2% | |
| Fees: legal | $931,278 | $769,053 | $162,225 | - | 1.1% | |
| All other expenses | $783,522 | $402,683 | $368,089 | $12,750 | 1.0% | |
| Information technology | $663,873 | $662,992 | - | $881 | 0.8% | |
| Fees: investment management | $266,229 | - | $266,229 | - | 0.3% | |
| Other (as described) | TELEPHONE & COMMUNICATI | $234,380 | $220,357 | $1,955 | $12,068 | 0.3% |
| Other (as described) | POSTAGE & DELIVERY | $158,314 | $152,800 | $1,655 | $3,859 | 0.2% |
| Fees: accounting | $156,050 | $11,000 | $145,050 | - | 0.2% | |
| Other (as described) | PRINTING & PUBLICATION | $155,459 | $149,782 | - | $5,677 | 0.2% |
| Royalties | $125,000 | $125,000 | - | - | 0.2% | |
| Total | $81,593,162 | 100% |
2013 · Form 990 · $78,842,979 spent · pay $40,654,911 · grants $0 · events $0
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $27,108,230 | $20,991,203 | $5,306,651 | $810,376 | 34.4% | |
| Office expenses | $7,923,921 | $7,918,415 | $82 | $5,424 | 10.1% | |
| Fees: other services | $7,161,681 | $6,671,860 | $439,020 | $50,801 | 9.1% | |
| Depreciation and depletion | $6,503,893 | $5,655,004 | $848,889 | - | 8.2% | |
| Interest | $5,891,551 | $5,072,140 | $819,411 | - | 7.5% | |
| Other employee benefits | $5,000,457 | $3,774,600 | $937,222 | $288,635 | 6.3% | |
| Pay: officers, directors, trustees, key employees | $4,113,157 | $3,384,257 | $728,900 | - | 5.2% | |
| Other (as described) | ANIMALS | $3,119,532 | $3,119,532 | - | - | 4.0% |
| Occupancy | $2,550,087 | $2,243,485 | $306,602 | - | 3.2% | |
| Pension plan contributions | $2,450,000 | $1,992,830 | $457,170 | - | 3.1% | |
| Payroll taxes | $1,983,067 | $1,613,037 | $370,030 | - | 2.5% | |
| Travel | $1,236,995 | $1,159,668 | $42,519 | $34,808 | 1.6% | |
| Insurance | $953,783 | $754,232 | $199,551 | - | 1.2% | |
| Fees: legal | $743,175 | $674,229 | $68,946 | - | 0.9% | |
| Other (as described) | ALL OTHER EXPENSES | $567,520 | $555,483 | $1,410 | $10,627 | 0.7% |
| Information technology | $516,333 | $510,662 | - | $5,671 | 0.7% | |
| Fees: investment management | $254,315 | - | $254,315 | - | 0.3% | |
| Other (as described) | TELEPHONE & COMMUNICATI | $235,090 | $218,192 | $3,520 | $13,378 | 0.3% |
| Other (as described) | PRINTING & PUBLICATION | $157,228 | $150,132 | - | $7,096 | 0.2% |
| All other expenses | $134,347 | $132,294 | $939 | $1,114 | 0.2% | |
| Fees: accounting | $129,626 | $126 | $129,500 | - | 0.2% | |
| Royalties | $108,991 | $108,991 | - | - | 0.1% | |
| Total | $78,842,979 | 100% |
2012 · Form 990 · $82,921,017 spent · pay $40,086,918 · grants $0 · events $0
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $26,987,742 | $20,035,747 | $5,903,011 | $1,048,984 | 32.5% | |
| Other (as described) | SUBCONTRACTED RESEARCH | $8,319,989 | $8,319,989 | - | - | 10.0% |
| Office expenses | $7,981,616 | $7,973,001 | $150 | $8,465 | 9.6% | |
| Depreciation and depletion | $6,319,854 | $5,410,020 | $909,834 | - | 7.6% | |
| Interest | $6,069,502 | $5,047,281 | $1,022,221 | - | 7.3% | |
| Other employee benefits | $4,764,422 | $3,558,041 | $885,428 | $320,953 | 5.7% | |
| Pay: officers, directors, trustees, key employees | $4,000,232 | $3,286,290 | $713,942 | - | 4.8% | |
| Fees: other services | $3,400,344 | $2,781,323 | $562,402 | $56,619 | 4.1% | |
| Other (as described) | ANIMALS | $2,918,017 | $2,918,017 | - | - | 3.5% |
| Pension plan contributions | $2,526,036 | $2,058,940 | $467,096 | - | 3.0% | |
| Occupancy | $2,416,960 | $2,095,507 | $321,453 | - | 2.9% | |
| Payroll taxes | $1,808,486 | $1,497,089 | $311,397 | - | 2.2% | |
| Travel | $1,385,594 | $1,295,418 | $20,848 | $69,328 | 1.7% | |
| Insurance | $925,082 | $735,726 | $189,356 | - | 1.1% | |
| Other (as described) | OTHER EXPENSES | $713,291 | $674,581 | -$4,544 | $43,254 | 0.9% |
| Fees: legal | $702,474 | $533,410 | $169,064 | - | 0.8% | |
| Information technology | $515,055 | $496,665 | - | $18,390 | 0.6% | |
| All other expenses | $382,247 | $357,102 | $5,696 | $19,449 | 0.5% | |
| Other (as described) | PRINTING & PUBLICATION | $249,059 | $243,104 | $1,860 | $4,095 | 0.3% |
| Fees: investment management | $211,732 | - | $211,732 | - | 0.3% | |
| Royalties | $200,000 | $200,000 | - | - | 0.2% | |
| Fees: accounting | $123,283 | $188 | $123,095 | - | 0.1% | |
| Total | $82,921,017 | 100% |
2011 · Form 990 · $86,638,584 spent · pay $37,893,472 · grants $0 · events $0
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $25,063,704 | $22,818,178 | $1,424,749 | $820,777 | 28.9% | |
| Fees: other services | $18,866,459 | $18,590,209 | $250,819 | $25,431 | 21.8% | |
| Office expenses | $7,645,412 | $7,588,785 | $20,909 | $35,718 | 8.8% | |
| Interest | $6,615,085 | $6,379,747 | $235,338 | - | 7.6% | |
| Depreciation and depletion | $5,865,492 | $5,813,638 | $51,854 | - | 6.8% | |
| Other employee benefits | $4,566,518 | $3,969,734 | $312,143 | $284,641 | 5.3% | |
| Pay: officers, directors, trustees, key employees | $4,049,403 | $2,849,113 | $1,200,290 | - | 4.7% | |
| Occupancy | $2,832,118 | $2,787,163 | $42,852 | $2,103 | 3.3% | |
| Other (as described) | ANIMALS | $2,702,268 | $2,702,268 | - | - | 3.1% |
| Pension plan contributions | $2,507,603 | $2,417,769 | $89,834 | - | 2.9% | |
| Payroll taxes | $1,706,244 | $1,639,985 | $66,259 | - | 2.0% | |
| Travel | $1,211,209 | $1,070,225 | $65,981 | $75,003 | 1.4% | |
| Insurance | $912,690 | $801,533 | $111,157 | - | 1.1% | |
| Fees: legal | $740,449 | $421,316 | $266,916 | $52,217 | 0.9% | |
| Information technology | $648,956 | $632,353 | $923 | $15,680 | 0.7% | |
| Fees: investment management | $211,118 | - | $211,118 | - | 0.2% | |
| Other (as described) | PRINTING AND PUBLICATIO | $182,944 | $155,002 | $42 | $27,900 | 0.2% |
| Other (as described) | POSTAGE AND SHIPPING | $178,019 | $159,222 | $12,667 | $6,130 | 0.2% |
| Fees: professional fundraisers | $150,301 | - | - | $150,301 | 0.2% | |
| Royalties | $144,850 | $144,850 | - | - | 0.2% | |
| Fees: accounting | $142,882 | $5,843 | $137,039 | - | 0.2% | |
| Other (as described) | LAB ADMINISTRATION ALLO | $0 | $2,433,135 | -$2,433,135 | - | 0.0% |
| All other expenses | -$305,140 | -$354,330 | $1,033 | $48,157 | -0.4% | |
| Total | $86,638,584 | 100% |
2010 · Form 990 · $78,754,762 spent · pay $34,156,788 · grants $0 · events $21,275
| Line | As described | Total | Program | Management | Fundraising | Share |
|---|---|---|---|---|---|---|
| Other salaries and wages | $23,538,849 | $22,552,618 | $533,032 | $453,199 | 29.9% | |
| Fees: other services | $16,681,137 | $16,548,270 | $59,255 | $73,612 | 21.2% | |
| Office expenses | $6,547,560 | $6,530,884 | $11,161 | $5,515 | 8.3% | |
| Interest | $5,816,184 | $5,683,874 | $132,310 | - | 7.4% | |
| Depreciation and depletion | $4,816,044 | $4,815,540 | $504 | - | 6.1% | |
| Other employee benefits | $3,821,034 | $3,612,491 | $56,288 | $152,255 | 4.9% | |
| Pay: officers, directors, trustees, key employees | $2,966,115 | $2,233,327 | $732,788 | - | 3.8% | |
| Occupancy | $2,714,274 | $2,661,624 | $21,334 | $31,316 | 3.4% | |
| Other (as described) | ANIMALS | $2,493,976 | $2,493,976 | - | - | 3.2% |
| Pension plan contributions | $2,324,107 | $2,240,127 | $83,980 | - | 3.0% | |
| Payroll taxes | $1,506,683 | $1,480,552 | $26,131 | - | 1.9% | |
| Travel | $1,199,561 | $1,161,286 | $7,255 | $31,020 | 1.5% | |
| Insurance | $955,115 | $902,906 | $52,209 | - | 1.2% | |
| Fees: legal | $907,768 | $809,852 | $97,046 | $870 | 1.2% | |
| Information technology | $655,516 | $628,783 | $429 | $26,304 | 0.8% | |
| Royalties | $475,470 | $475,470 | - | - | 0.6% | |
| Other (as described) | PRINTING AND PUBLICATIO | $311,636 | $300,330 | - | $11,306 | 0.4% |
| Fees: professional fundraisers | $303,701 | - | - | $303,701 | 0.4% | |
| Fees: investment management | $206,880 | - | $206,880 | - | 0.3% | |
| Other (as described) | OTHER/ACCRUALS | $154,641 | $145,442 | $1,702 | $7,497 | 0.2% |
| Other (as described) | POSTAGE AND SHIPPING | $147,657 | $139,029 | $6,413 | $2,215 | 0.2% |
| Fees: accounting | $117,700 | $82,390 | $35,310 | - | 0.1% | |
| Other (as described) | DUES AND SUBSCRIPTIONS | $54,935 | $36,523 | $4,770 | $13,642 | 0.1% |
| All other expenses | $38,219 | $35,747 | $100 | $2,372 | 0.0% | |
| Fundraising events Event | direct expenses; gross income - | $21,275 | reported apart | |||
| Total | $78,754,762 | 100% |
Federal lobbying
Lobbying Disclosure Act reports naming a client or registrant with this organization's name and state. Spent: what lobbying for it cost (firm income plus its own reported expenses). Earned: income it reported as a lobbying firm.
| Year | Spent | Earned | Reports |
|---|---|---|---|
| 2011 | $160,000 | 2 | |
| 2010 | $320,000 | 4 | |
| 2009 | $320,000 | 5 |
Issues: Budget/Appropriations, Defense, Medical/Disease Research/Clinical Labs
Firms hired: PODESTA GROUP, INC.
Federal grants and contracts
Awards from USAspending.gov to a recipient with this organization's name and zip code. Obligations by federal fiscal year (October to September); each award links to its page on usaspending.gov.
| Fiscal year | Grants and other assistance | Contracts | Awards |
|---|---|---|---|
| 2026 | $46,068,569 | $17,771 | 84 |
| 2025 | $49,487,226 | $23,573 | 82 |
| 2024 | $41,318,850 | $32,101 | 74 |
| 2023 | $40,503,385 | -$116,841 | 77 |
| 2022 | $46,811,590 | $636,081 | 75 |
| 2021 | $48,048,174 | $0 | 74 |
| 2020 | $31,740,834 | $0 | 64 |
| 2019 | $47,847,385 | $200,000 | 64 |
| 2018 | $32,308,081 | $0 | 54 |
| 2017 | $40,909,044 | $0 | 75 |
| 2016 | $1,207,500 | $0 | 3 |
| 2015 | $395,000 | $0 | 1 |
| 2014 | $692,247 | $0 | 2 |
| 2013 | $381,324 | $0 | 1 |
| 2011 | $734,964 | $0 | 1 |
Largest awards · 200 shown
| Year | Agency | Kind | Program | Description | Obligated |
|---|---|---|---|---|---|
| 2026 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | HOPE - HIV OBSTRUCTION BY PROGRAMMED EPIGENETICS - PROJECT SUMMARY/ABSTACT AFTER 40 YEARS, A CURE FOR PEOPLE LIVING WITH HIV (PLWH) REMAINS BOTH ELUSIVE AND ONE | $4,870,431 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | TRANSCRIPTIONAL AND POST-TRANSCRIPTIONAL REGULATION OF HUMAN TREG IDENTITY AND FUNCTION - ABSTRACT REGULATORY T CELLS (TREGS) ARE ESSENTIAL FOR MAINTAINING IMMU | $3,601,712 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | PHAIGE THERAPY CENTER: AI-GUIDED TAILSPIKE ENGINEERING AND MOLECULAR TYPING FOR RAPID PHAGE DESIGN AND TESTING AGAINST ESKAPE PATHOGENS - PROJECT SUMMARY/ABSTRA | $2,047,959 |
| 2026 | National Institutes of Health | Grant or other assistance | DRUG USE AND ADDICTION RESEARCH PROGRAMS 93.279 | SORTING AND SEQUENCING LATENT RESERVOIRS IN HIV+ OPIOID USERS - ABSTRACT OPIOID USERS ARE PRIME BENEFICIARIES OF CURE STRATEGIES FOR HIV DUE TO THEIR MEDICAL AN | $1,550,268 |
| 2026 | National Institutes of Health | Grant or other assistance | TRANS-NIH RESEARCH SUPPORT 93.310 | A REVITALIZED FRAMEWORK FOR VITAMIN BIOLOGY: NEW SENSORS, PATHWAYS AND PRECISION THERAPIES - PROJECT SUMMARY OUR RESEARCH PROJECT SEEKS TO FUNDAMENTALLY TRANSF | $1,321,208 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | ELUCIDATING MICROVASCULAR CONTRIBUTIONS TO COGNITIVE IMPAIRMENT AT SINGLE-CELL RESOLUTION - PROJECT SUMMARY/ABSTRACT DEMENTIA AFFLICTS OVER 55 MILLION PEOPLE WO | $1,165,596 |
| 2026 | National Institutes of Health | Grant or other assistance | DRUG USE AND ADDICTION RESEARCH PROGRAMS 93.279 | STUDYING NEUROHIV AND ADDICTIVE SUBSTANCES IN A HUMAN MICROGLIA-NEURON CHIMERA MOUSE MODEL - PROJECT SUMMARY HIV AND SUBSTANCE USE DISORDER (SUD) ALTER BRAIN FU | $1,140,888 |
| 2026 | National Institutes of Health | Grant or other assistance | TRANS-NIH RESEARCH SUPPORT 93.310 | TRANSFER LEARNING LEVERAGING LARGE-SCALE TRANSCRIPTOMICS TO MAP DISRUPTED GENE NETWORKS IN CARDIOVASCULAR DISEASE - PROJECT SUMMARY/ABSTRACT MAPPING THE GENE RE | $945,000 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | ROLES OF TREM2 AND TYROBP IN AD-RELATED NETWORK HYPEREXCITABILITY - SUMMARY RECENT EVIDENCE SUGGESTS THAT IMMUNE AND NEURAL NETWORK DYSFUNCTIONS FORM A VICIOUS | $944,363 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | DEVELOP AD CONNECTIVITY MAPS WITH HUMAN IPSC-DERIVED BRAIN CELLS AND THEIR USE - SUMMARY ALZHEIMER’S DISEASE (AD) IS A MULTIFACTORIAL NEURODEGENERATIVE DISORDER | $943,826 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | STUDY ALZHEIMER'S DISEASE PROTECTIVE APOE VARIANTS - PROJECT SUMMARY THE COMPLEXITY AND MULTIFACTORIAL NATURE OF ALZHEIMER’S DISEASE (AD) POSE UNIQUE CHALLENGES | $941,364 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | GENETIC DISSECTION OF THE 17Q21.31 MAPT LOCUS IN NEURODEGENERATIVE DISEASE - PROJECT SUMMARY / ABSTRACT ALZHEIMER’S DISEASE AND RELATED DEMENTIAS MANIFEST WITH | $940,817 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | MACHINE LEARNING DISCOVERY OF VARIANTS THAT ALTER GENE REGULATION IN CARDIOVASCULAR DEVELOPMENT AND DISEASE - PROJECT SUMMARY / ABSTRACT CONGENITAL HEART DISEAS | $925,796 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | UNDO-HIV: UNDERSTANDING AND OBLITERATING THE ACTIVE HIV RESERVOIR - PROJECT SUMMARY A SUBSTANTIAL FRACTION OF THE HIV RESERVOIR THAT PERSISTS IN THE FACE OF ANT | $896,029 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | TARGETING THE TRANSCRIPTIONALLY-ACTIVE RESERVOIR TO REDUCE CHRONIC INFLAMMATION IN AGED PEOPLE WITH HIV - PROJECT SUMMARY RECENT DATA SUGGEST THAT A SUBSTANTIA | $890,051 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | STUDY SUSCEPTIBILITY AND RESISTANCE TO APOE4 IN ALZHEIMER'S DISEASE - SUMMARY THE COMPLEXITY AND MULTIFACTORIAL NATURE OF ALZHEIMER’S DISEASE (AD) POSE UNIQUE C | $879,003 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | FUNCTIONALIZATION OF RARE NONCODING VARIANTS AS DRIVERS OF ALZHEIMER'S DISEASE RISK - PROJECT SUMMARY / ABSTRACT ALZHEIMER’S DISEASE (AD) MANIFESTS AS AN AGE-RE | $845,617 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | EXPLORING NOX2-MEDIATED NETWORK IMPAIRMENT AND NEURODEGENERATION IN ALZHEIMER'S DISEASE - PROJECT SUMMARY THE COMPLEXITY AND MULTIFACTORIAL NATURE OF ALZHEIMER’ | $842,175 |
| 2026 | National Institutes of Health | Grant or other assistance | HUMAN GENOME RESEARCH 93.172 | METHODS TO BUILD AND ANNOTATE TISSUE ATLASES USING SPATIAL GENOMIC DATA - PROJECT SUMMARY/ABSTRACT SINGLE-CELL SPATIAL TECHNOLOGIES HOLD THE PROMISE OF UNDERSTA | $829,659 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | DISSECTING THE ETIOLOGY OF THE LEWY BODY DEMENTIAS - PROJECT SUMMARY LEWY BODY DEMENTIA (LBD) IS THE SECOND MOST COMMON NEURODEGENERATIVE DISORDER, AFFLICTING 1 | $822,417 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | HARNESSING NOVEL MACHINE LEARNING APPROACHES FOR BEHAVIORAL SEGMENTATION AND BRAIN SIGNAL INTEGRATION IN HUMANIZED MODELS OF ALZHEIMER'S DISEASE - SUMMARY RECEN | $817,357 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | UNDERSTANDING APOE4-INDUCED METABOLIC SHIFTS IN ALZHEIMER'S DISEASE - PROJECT SUMMARY THE APOE4 ALLELE IS THE STRONGEST AND MOST PREVALENT GENETIC RISK FACTOR F | $801,193 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | MITOCHONDRIAL DNA COMPACTION AND THE ACCUMULATION OF MUTATIONS WITH AGE AND STRESS - PROJECT SUMMARY/ABSTRACT THE PRIMARY GOAL OF THIS PROJECT IS TO UNDERSTAND | $793,777 |
| 2026 | National Institutes of Health | Grant or other assistance | TRANS-NIH RESEARCH SUPPORT 93.310 | CARDIOGENESIS: MOLECULAR MECHANISMS | $787,185 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | SMALL MOLECULE THERAPEUTIC FOR CALCIFIC AORTIC VALVE DISEASE - PROJECT SUMMARY AORTIC VALVE STENOSIS IS THE MAJOR CAUSE OF VALVE DISEASE IN THE WESTERN WORLD, A | $782,141 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | TARGETING NELL2 AND GABAERGIC DYSFUNCTION TO MITIGATE APOE4-DRIVEN PATHOGENESIS IN ALZHEIMER'S DISEASE - PROJECT SUMMARY THE COMPLEXITY AND MULTIFACTORIAL NATUR | $778,757 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | EPIGENOMIC MECHANISMS OF CARDIAC FIBROSIS AND HEART FAILURE - PROJECT SUMMARY A HEART FAILURE DIAGNOSIS LEADS TO POOR QUALITY OF LIFE AND A 5-YEAR MORTALITY NEA | $773,842 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | CHROMATIN REGULATION OF IMMUNE CELLS IN MYOCARDIAL INFLAMMATION - PROJECT SUMMARY ISCHEMIC HEART DISEASE FOLLOWING MYOCARDIAL INFARCTION (MI) IS A LEADING CAUSE | $765,888 |
| 2026 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | MULTIOMICS CHARACTERIZATION, INDUCTION, AND ELIMINATION OF THE HIV GUT RESERVOIR - PROJECT SUMMARY STUDIES IN ANIMAL MODELS HAVE SUGGESTED 98% OF THE HIV RESER | $758,183 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | DECODING AND REPROGRAMMING T CELLS THROUGH SYNTHETIC BIOLOGY FOR CANCER IMMUNOTHERAPY - ABSTRACT ENGINEERED T CELL-BASED CANCER THERAPIES ARE A MAJOR ADVANCEMEN | $749,187 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 | COMPUTATIONAL PREDICTION OF ANTI-CANCER DRUG METABOLIZING ENZYMES IN THE HUMAN MICROBIOME - PROJECT SUMMARY DRUGS CAN BE MODIFIED BY HUMAN GUT BACTERIA, LEADING | $747,790 |
| 2026 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | ROLE OF FACTOR ACETYLATION IN THE REGULATION OF HIV TRANSCRIPTION | $737,100 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | EARLY CARDIAC PROGENITORS | $718,069 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | MECHANISMS OF OXYGEN TOXICITY - PROJECT SUMMARY/ABSTRACT EXCESS OXYGEN OR “HYPEROXIA” IS TOXIC ACROSS ALL THREE DOMAINS OF LIFE. A RANGE OF PATHOLOGIES ARISE F | $717,190 |
| 2026 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | ENGINEERING REGIONALLY SPECIFIC TRANSPLANTS FOR NEUROMODULATION-DRIVEN SCI REPAIR - PROJECT SUMMARY CERVICAL SPINAL CORD INJURY (SCI) RESULTS IN DEBILITATING DE | $716,750 |
| 2026 | National Institutes of Health | Grant or other assistance | ENVIRONMENTAL HEALTH 93.113 | INVESTIGATING NOVEL GENETIC VARIANTS THAT CONFER SUSCEPTIBILITY TO PESTICIDE-INDUCED PARKINSON'S DISEASE - PROJECT SUMMARY/ABSTRACT EXPOSURE TO VARIOUS PESTICID | $706,158 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | A SPATIAL PROFILING-BASED IMMUNE HUB PERTURBATION PLATFORM TO IMPROVE IMMUNOTHERAPY IN COLON CANCER - PROJECT SUMMARY CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THE | $661,005 |
| 2026 | National Institutes of Health | Grant or other assistance | DRUG USE AND ADDICTION RESEARCH PROGRAMS 93.279 | TARGETED SMALL MOLECULE RECRUITMENT TO SUPPRESS THE HIV TRANSCRIPTIONALLY ACTIVE RESERVOIR - PROJECT SUMMARY/ABSTRACT ANTIRETROVIRAL THERAPY (ART), INTRODUCED N | $655,855 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | PROTEOSTASIS, NEUROINFLAMMATION AND NEURODEGENERATION IN FRONTOTEMPORAL DEMENTIA - PROTEOSTASIS IMPAIRMENT, INFLAMMATION AND GLIOSIS ARE LINKED TO NEURODEGENERA | $607,816 |
| 2026 | National Institutes of Health | Grant or other assistance | CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 | EFFECTS OF PREP DRUGS ON FEMALE GENITAL HIV INFECTION AND WOMEN'S REPRODUCTIVE HEALTH - PROJECT SUMMARY WORLDWIDE, YOUNG REPRODUCTIVE AGE WOMEN ACCOUNT FOR THE | $599,720 |
| 2026 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | UNDERSTANDING AND TREATING NAXD DEFICIENCY USING VITAMIN B3-BASED APPROACHES - PROJECT SUMMARY THE PAST DECADE HAS SEEN SIGNIFICANT INTEREST IN VITAMIN B3 THER | $574,921 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | MECHANISTIC EXPLORATION OF TREM2 ANTIBODIES THAT CAN SUPPRESS ALZHEIMER'S DISEASE RELATED NETWORK HYPEREXCITABILITY AND COGNITIVE DEFICITS - SUMMARY ALZHEIMER’S | $519,750 |
| 2026 | National Institutes of Health | Grant or other assistance | CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 | ENGINEERING TARGETED DELIVERY VEHICLES FOR GENOME EDITING IN HEMATOPOIETIC STEM CELLS - PROJECT SUMMARY/ABSTRACT THE ADVENT OF GENOME EDITING PROVIDES THE OPPOR | $485,966 |
| 2026 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | OPC-X SCREEN: DISCOVERY OF SMALL MOLECULE INHIBITORS TO OVERCOME EXTRINSIC INHIBITION OF REMYELINATION. - PROJECT SUMMARY/ABSTRACT MULTIPLE SCLEROSIS (MS) IS A | $472,500 |
| 2026 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | ROLE OF MYELOID AND CD4+ T IMMUNE CELLS IN POST-TRAUMATIC PLASTICITY - ABSTRACT TRAUMATIC BRAIN INJURY (TBI) IMPACTS MILLIONS OF AMERICANS EACH YEAR AND CAN LEA | $412,400 |
| 2026 | National Institutes of Health | Grant or other assistance | ORAL DISEASES AND DISORDERS RESEARCH 93.121 | DEFINING MOLECULAR INTERACTIONS BETWEEN COMMENSAL RESPIRATORY VIRUSES AND THE HUMAN HOST - PROJECT SUMMARY/ABSTRACT WHILE RESPIRATORY PATHOGENS HAVE RECEIVED SI | $378,000 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | ADDRESSING DISPARITIES IN POLYGENIC RISK SCORE FOR CORONARY HEART DISEASES IN DIVERSE POPULATIONS - PROJECT SUMMARY/ABSTRACT CORONARY HEART DISEASE (CHD) REMAIN | $179,280 |
| 2026 | National Institutes of Health | Grant or other assistance | RESEARCH INFRASTRUCTURE PROGRAMS 93.351 | ROCHE DISCOVERY ULTRA - PROJECT SUMMARY/ABSTRACT: THE HISTOLOGY AND LIGHT MICROSCOPY CORE (HLMC) AT GLADSTONE HAS BEEN ESTABLISHED FOR MORE THAN TWENTY YEARS AN | $175,000 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | PROMOTING UNDERREPRESENTED MINORITY ADVANCEMENT IN THE SCIENCES (PUMAS) | $166,320 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | UNCOVERING THE MECHANISMS THAT ENABLE CARDIAC PROGENITORS TO BUILD THE LINEAR HEART TUBE - PROJECT SUMMARY CONGENITAL HEART DEFECTS (CHDS) OCCUR IN APPROXIMATE | $134,998 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | LINKING MICROBES TO CARDIOVASCULAR-ASSOCIATED METABOLITES USING KNOWLEDGE-BASED MACHINE LEARNING - PROJECT SUMMARY THE GUT MICROBIOME PRODUCES NUMEROUS METABOLI | $134,439 |
| 2026 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | DISSECTING THE CHROMATIN AND SPATIAL MECHANISMS OF HMGN1-MEDIATEDCONGENITAL HEART DEFECTS IN DOWN SYNDROME - PROJECT SUMMARY/ABSTRACT CONGENITAL HEART DEFECTS ( | $131,307 |
| 2026 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | MICROGLIAL CONTROL OF THALAMOCORTICAL CIRCUITS IN ALZHEIMER'S DISEASE - PROJECT SUMMARY / ABSTRACT ALZHEIMER’S DISEASE (AD) IS A NEURODEGENERATIVE DISORDER AFFE | $122,850 |
| 2026 | National Institutes of Health | Grant or other assistance | CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 | TRANSCRIPTIONAL VARIATION IN HUMAN MILK - PROJECT SUMMARY THE CENTERS FOR DISEASE CONTROL RECOMMENDS BREASTFEEDING FOR THE FIRST SIX MONTHS OF AN INFANT’S LIFE | $82,348 |
| 2026 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | CELL TYPE-SPECIFIC PERIPHERAL IMMUNE RESPONSE AS A BIOMARKER AND THERAPEUTIC TARGET FOR ALZHEIMER'S DISEASE - PROJECT SUMMARY ALZHEIMER’S DISEASE (AD) AFFECTS O | $79,348 |
| 2026 | Department of Veterans Affairs | Contract | ANALYTICAL LABORATORY INSTRUMENT MANUFACTURING 334516 | GLADSTONE FLOW CYTOMETRY CORE | $26,589 |
| 2026 | Department of Veterans Affairs | Contract | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) 541714 | GLADSTONE CORE SERVICES | $4,500 |
| 2026 | Department of Veterans Affairs | Contract | ANALYTICAL LABORATORY INSTRUMENT MANUFACTURING 334516 | FY24-FY25 FLOW CYTOMETER CORE USE FOR RESEARCH | -$13,317 |
| 2025 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | HOPE - HIV OBSTRUCTION BY PROGRAMMED EPIGENETICS - PROJECT SUMMARY/ABSTACT AFTER 40 YEARS, A CURE FOR PEOPLE LIVING WITH HIV (PLWH) REMAINS BOTH ELUSIVE AND ONE | $4,951,244 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | DECODING THE MULTIFACTORIAL ETIOLOGY OF NEURAL NETWORK DYSFUNCTION IN ALZHEIMER'S DISEASE - SUPPLEMENT – SUMMARY TAU CONTRIBUTES TO ALZHEIMER’S DISEASE (AD) AND | $4,564,091 |
| 2025 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | TRANSFORMING HIV VACCINE DESIGN WITH A HYBRID TECHNOLOGY THAT LEVERAGES FEATURES OF MRNA AND PROTEIN NANOPARTICLE PLATFORMS - PROPOSAL SUMMARY/ABSTRACT THE HIV- | $3,559,750 |
| 2025 | National Institutes of Health | Grant or other assistance | DRUG USE AND ADDICTION RESEARCH PROGRAMS 93.279 | SORTING AND SEQUENCING LATENT RESERVOIRS IN HIV+ OPIOID USERS - ABSTRACT OPIOID USERS ARE PRIME BENEFICIARIES OF CURE STRATEGIES FOR HIV DUE TO THEIR MEDICAL AN | $1,557,466 |
| 2025 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | TARGETING FEEDBACK CIRCUITRY FOR ANTIVIRAL THERAPY - PROJECT SUMMARY/ABSTRACT THE HUMAN HERPESVIRUS 5 (CYTOMEGALOVIRUS, CMV) INFECTS >50% OF THE WORLD’S POPULAT | $1,510,374 |
| 2025 | National Science Foundation | Grant or other assistance | BIOLOGICAL SCIENCES 47.074 | MECHANISMS OF NON-CANONICAL RETRON PHAGE DEFENSE AND EXPANDED BIOTECHNOLOGICAL APPLICATIONS -RETRONS ARE BACTERIAL IMMUNE SYSTEMS THAT SENSE WHEN A CELL IS INFE | $1,500,004 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | ENHANCER-AAVS TO MONITOR AND RESTORE CELL-TYPE SELECTIVE INHIBITORY DEFICITS AND CIRCUIT DYSFUNCTION IN HUMANIZED ALZHEIMER'S DISEASE MODELS - SUMMARY ALZHEIMER | $1,459,072 |
| 2025 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | NEUROVASCULAR INTERACTIONS: MECHANISMS, IMAGING, THERAPEUTICS - THE NEUROVASCULAR INTERFACE FUNDAMENTALLY CHANGES DURING CNS DISEASES DUE TO INCREASED BLOOD-BRA | $1,375,478 |
| 2025 | National Institutes of Health | Grant or other assistance | TRANS-NIH RESEARCH SUPPORT 93.310 | A REVITALIZED FRAMEWORK FOR VITAMIN BIOLOGY: NEW SENSORS, PATHWAYS AND PRECISION THERAPIES - PROJECT SUMMARY OUR RESEARCH PROJECT SEEKS TO FUNDAMENTALLY TRANSF | $1,321,208 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | ELUCIDATING MICROVASCULAR CONTRIBUTIONS TO COGNITIVE IMPAIRMENT AT SINGLE-CELL RESOLUTION - PROJECT SUMMARY/ABSTRACT DEMENTIA AFFLICTS OVER 55 MILLION PEOPLE WO | $1,269,827 |
| 2025 | National Institutes of Health | Grant or other assistance | MENTAL HEALTH RESEARCH GRANTS 93.242 | STUDYING NEUROHIV AND ADDICTIVE SUBSTANCES IN A HUMAN MICROGLIA-NEURON CHIMERA MOUSE MODEL - PROJECT SUMMARY HIV AND SUBSTANCE USE DISORDER (SUD) ALTER BRAIN FU | $1,088,600 |
| 2025 | National Institutes of Health | Grant or other assistance | ORAL DISEASES AND DISORDERS RESEARCH 93.121 | SELF-ASSEMBLING SPIKE-EBR NANOPARTICLES AS A VACCINE PLATFORM TECHNOLOGY AGAINST SARS-COV-2 AND FUTURE PANDEMIC CORONAVIRUSES. - PROJECT SUMMARY/ABSTRACT THE CO | $945,000 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | DEVELOP AD CONNECTIVITY MAPS WITH HUMAN IPSC-DERIVED BRAIN CELLS AND THEIR USE - SUMMARY ALZHEIMER’S DISEASE (AD) IS A MULTIFACTORIAL NEURODEGENERATIVE DISORDER | $922,930 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | STUDY ALZHEIMER'S DISEASE PROTECTIVE APOE VARIANTS - PROJECT SUMMARY THE COMPLEXITY AND MULTIFACTORIAL NATURE OF ALZHEIMER’S DISEASE (AD) POSE UNIQUE CHALLENGES | $922,536 |
| 2025 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | TARGETING THE TRANSCRIPTIONALLY-ACTIVE RESERVOIR TO REDUCE CHRONIC INFLAMMATION IN AGED PEOPLE WITH HIV - PROJECT SUMMARY RECENT DATA SUGGEST THAT A SUBSTANTIA | $891,217 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | STUDY SUSCEPTIBILITY AND RESISTANCE TO APOE4 IN ALZHEIMER'S DISEASE - SUMMARY THE COMPLEXITY AND MULTIFACTORIAL NATURE OF ALZHEIMER’S DISEASE (AD) POSE UNIQUE C | $861,422 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | EXPLORING NOX2-MEDIATED NETWORK IMPAIRMENT AND NEURODEGENERATION IN ALZHEIMER'S DISEASE - PROJECT SUMMARY THE COMPLEXITY AND MULTIFACTORIAL NATURE OF ALZHEIMER’ | $842,175 |
| 2025 | National Institutes of Health | Grant or other assistance | HUMAN GENOME RESEARCH 93.172 | METHODS TO BUILD AND ANNOTATE TISSUE ATLASES USING SPATIAL GENOMIC DATA - PROJECT SUMMARY/ABSTRACT SINGLE-CELL SPATIAL TECHNOLOGIES HOLD THE PROMISE OF UNDERSTA | $829,659 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | HARNESSING NOVEL MACHINE LEARNING APPROACHES FOR BEHAVIORAL SEGMENTATION AND BRAIN SIGNAL INTEGRATION IN HUMANIZED MODELS OF ALZHEIMER'S DISEASE - SUMMARY RECEN | $817,357 |
| 2025 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | EPIGENOMIC MECHANISMS OF CARDIAC FIBROSIS AND HEART FAILURE - PROJECT SUMMARY A HEART FAILURE DIAGNOSIS LEADS TO POOR QUALITY OF LIFE AND A 5-YEAR MORTALITY NEA | $811,885 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | TARGETING NELL2 AND GABAERGIC DYSFUNCTION TO MITIGATE APOE4-DRIVEN PATHOGENESIS IN ALZHEIMER'S DISEASE - PROJECT SUMMARY THE COMPLEXITY AND MULTIFACTORIAL NATUR | $804,450 |
| 2025 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | CHROMATIN REGULATION OF IMMUNE CELLS IN MYOCARDIAL INFLAMMATION - PROJECT SUMMARY ISCHEMIC HEART DISEASE FOLLOWING MYOCARDIAL INFARCTION (MI) IS A LEADING CAUSE | $803,768 |
| 2025 | National Institutes of Health | Grant or other assistance | TRANS-NIH RESEARCH SUPPORT 93.310 | CARDIOGENESIS: MOLECULAR MECHANISMS | $803,250 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | NEURONAL APOE DRIVES SELECTIVE NEURODEGENERATION IN ALZHEIMER'S DISEASE - PROJECT SUMMARY SELECTIVE NEURODEGENERATION IS A CRITICAL CAUSAL FACTOR IN ALZHEIMER’S | $800,972 |
| 2025 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | SMALL MOLECULE THERAPEUTIC FOR CALCIFIC AORTIC VALVE DISEASE - PROJECT SUMMARY AORTIC VALVE STENOSIS IS THE MAJOR CAUSE OF VALVE DISEASE IN THE WESTERN WORLD, A | $798,104 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | MITOCHONDRIAL DNA COMPACTION AND THE ACCUMULATION OF MUTATIONS WITH AGE AND STRESS - PROJECT SUMMARY/ABSTRACT THE PRIMARY GOAL OF THIS PROJECT IS TO UNDERSTAND | $793,777 |
| 2025 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | EARLY CARDIAC PROGENITORS | $777,297 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | DISSECTING THE ETIOLOGY OF THE LEWY BODY DEMENTIAS - PROJECT SUMMARY LEWY BODY DEMENTIA (LBD) IS THE SECOND MOST COMMON NEURODEGENERATIVE DISORDER, AFFLICTING 1 | $764,836 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | DECODING AND REPROGRAMMING T CELLS THROUGH SYNTHETIC BIOLOGY FOR CANCER IMMUNOTHERAPY - ABSTRACT ENGINEERED T CELL-BASED CANCER THERAPIES ARE A MAJOR ADVANCEMEN | $749,187 |
| 2025 | National Institutes of Health | Grant or other assistance | CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 | EFFECTS OF PREP DRUGS ON FEMALE GENITAL HIV INFECTION AND WOMEN'S REPRODUCTIVE HEALTH - PROJECT SUMMARY WORLDWIDE, YOUNG REPRODUCTIVE AGE WOMEN ACCOUNT FOR THE | $747,000 |
| 2025 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | ROLE OF FACTOR ACETYLATION IN THE REGULATION OF HIV TRANSCRIPTION | $737,100 |
| 2025 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | MECHANISMS OF OXYGEN TOXICITY - PROJECT SUMMARY/ABSTRACT EXCESS OXYGEN OR “HYPEROXIA” IS TOXIC ACROSS ALL THREE DOMAINS OF LIFE. A RANGE OF PATHOLOGIES ARISE F | $731,827 |
| 2025 | National Institutes of Health | Grant or other assistance | ENVIRONMENTAL HEALTH 93.113 | INVESTIGATING NOVEL GENETIC VARIANTS THAT CONFER SUSCEPTIBILITY TO PESTICIDE-INDUCED PARKINSON'S DISEASE - PROJECT SUMMARY/ABSTRACT EXPOSURE TO VARIOUS PESTICID | $728,408 |
| 2025 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | MULTIOMICS CHARACTERIZATION, INDUCTION, AND ELIMINATION OF THE HIV GUT RESERVOIR - PROJECT SUMMARY STUDIES IN ANIMAL MODELS HAVE SUGGESTED 98% OF THE HIV RESER | $724,238 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | A SPATIAL PROFILING-BASED IMMUNE HUB PERTURBATION PLATFORM TO IMPROVE IMMUNOTHERAPY IN COLON CANCER - PROJECT SUMMARY CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THE | $710,361 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | C9ORF72 FRONTOTEMPORAL DEMENTIA (FTD) AND AMYOTROPHIC LATERAL SCLEROSIS(ALS): USING PATIENT CELLS AND CRISPR TO REVEAL THERAPEUTIC APPROACHES - PROJECT SUMMARY/ | $694,575 |
| 2025 | National Institutes of Health | Grant or other assistance | DRUG USE AND ADDICTION RESEARCH PROGRAMS 93.279 | TARGETED SMALL MOLECULE RECRUITMENT TO SUPPRESS THE HIV TRANSCRIPTIONALLY ACTIVE RESERVOIR - PROJECT SUMMARY/ABSTRACT ANTIRETROVIRAL THERAPY (ART), INTRODUCED N | $687,416 |
| 2025 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | LINKING MICROBIOME GENETIC VARIANTS WITH CARDIOVASCULAR PHENOTYPES IN 50,000 INDIVIDUALS - PROJECT SUMMARY / ABSTRACT THE HUMAN BODY IS HOME TO A COMPLEX COMMUN | $685,007 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | PROTEOSTASIS, NEUROINFLAMMATION AND NEURODEGENERATION IN FRONTOTEMPORAL DEMENTIA - PROTEOSTASIS IMPAIRMENT, INFLAMMATION AND GLIOSIS ARE LINKED TO NEURODEGENERA | $630,496 |
| 2025 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | UNDERSTANDING AND TREATING NAXD DEFICIENCY USING VITAMIN B3-BASED APPROACHES - PROJECT SUMMARY THE PAST DECADE HAS SEEN SIGNIFICANT INTEREST IN VITAMIN B3 THER | $574,921 |
| 2025 | National Institutes of Health | Grant or other assistance | TRANS-NIH RESEARCH SUPPORT 93.310 | TRANSFER LEARNING LEVERAGING LARGE-SCALE TRANSCRIPTOMICS TO MAP DISRUPTED GENE NETWORKS IN CARDIOVASCULAR DISEASE - PROJECT SUMMARY/ABSTRACT MAPPING THE GENE RE | $472,500 |
| 2025 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | OPC-X SCREEN: DISCOVERY OF SMALL MOLECULE INHIBITORS TO OVERCOME EXTRINSIC INHIBITION OF REMYELINATION. - PROJECT SUMMARY/ABSTRACT MULTIPLE SCLEROSIS (MS) IS A | $472,500 |
| 2025 | National Institutes of Health | Grant or other assistance | MEDICAL LIBRARY ASSISTANCE 93.879 | IMAGE TOOLS FOR COMPUTATIONAL CELLULAR BARCODING AND AUTOMATED ANNOTATION - PROJECT SUMMARY WITH TECHNOLOGICAL BREAKTHROUGHS IN HIGH-THROUGHPUT SINGLE-CELL IMAG | $398,349 |
| 2025 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | ROLE OF MYELOID AND CD4+ T IMMUNE CELLS IN POST-TRAUMATIC PLASTICITY - ABSTRACT TRAUMATIC BRAIN INJURY (TBI) IMPACTS MILLIONS OF AMERICANS EACH YEAR AND CAN LEA | $371,162 |
| 2025 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | TARGETED DELIVERY OF CAS9 TO LUNG EPITHELIAL CELLS USING ENVELOPED DELIVERY VEHICLES - PROJECT SUMMARY/ABSTRACT THE RAPID DEVELOPMENT OF GENOME EDITING TOOLS HA | $283,500 |
| 2025 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | TARGETING CD127-EXPRESSING TISSUE RESERVOIR CELLS AS A STRATEGY FOR HIV CURE - PROJECT SUMMARY HOMEOSTATIC PROLIFERATION, IN PARTICULAR THAT MEDIATED BY IL7, I | $252,348 |
| 2025 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | ADDRESSING DISPARITIES IN POLYGENIC RISK SCORE FOR CORONARY HEART DISEASES IN DIVERSE POPULATIONS - PROJECT SUMMARY/ABSTRACT CORONARY HEART DISEASE (CHD) REMAIN | $179,280 |
| 2025 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | PROMOTING UNDERREPRESENTED MINORITY ADVANCEMENT IN THE SCIENCES (PUMAS) | $166,320 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | MACHINE LEARNING APPROACHES FOR BEHAVIORAL PHENOTYPING OF HUMANIZED KNOCK-IN MODELS OF ALZHEIMER'S DISEASE - PROJECT SUMMARY PRECLINICAL EFFORTS TO DEVELOP TREA | $150,630 |
| 2025 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | UNCOVERING THE MECHANISMS THAT ENABLE CARDIAC PROGENITORS TO BUILD THE LINEAR HEART TUBE - PROJECT SUMMARY CONGENITAL HEART DEFECTS (CHDS) OCCUR IN APPROXIMATE | $134,998 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | METABOLIC VULNERABILITY AND EFFECTS OF APOE IN HUMAN NEURONS WITH IMPAIRED ENDOCYTIC RECYCLING - PROJECT SUMMARY NEURODEGENERATIVE DEMENTIAS, INCLUDING ALZHEIME | $124,859 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | UNDERSTANDING HOW NEURONAL GLUCOSE METABOLISM CHANGES IN AD DUE TO APOE4 - PROJECT SUMMARY WITH RAPID IMPROVEMENTS TO THE QUALITY OF OUR HEALTHCARE, THERE IS AN | $85,360 |
| 2025 | National Institutes of Health | Grant or other assistance | CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 | TRANSCRIPTIONAL VARIATION IN HUMAN MILK - PROJECT SUMMARY THE CENTERS FOR DISEASE CONTROL RECOMMENDS BREASTFEEDING FOR THE FIRST SIX MONTHS OF AN INFANT’S LIFE | $78,520 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | INVESTIGATION INTO TRANSCRIPTOMIC CONTROL OF DENTATE GRANULE CELL MATURATION AND HYPEREXCITABILITY IN THE APOE4 ALZHEIMER'S DISEASE MODEL - PROJECT SUMMARY ALZH | $76,756 |
| 2025 | Department of Veterans Affairs | Contract | ANALYTICAL LABORATORY INSTRUMENT MANUFACTURING 334516 | FLOW CYTONMETER CORE USAGE FOR VA SAN FRANCISCO MEDICAL CENTER | $25,874 |
| 2025 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | AMERICAN SOCIETY FOR NEURAL THERAPY AND REPAIR ANNUAL CONFERENCE APRIL 2025 - ABSTRACT THIS R13 APPLICATION SEEKS FUNDING FOR OUR ANNUAL AMERICAN SOCIETY FOR NE | $10,000 |
| 2025 | Department of Veterans Affairs | Contract | ANALYTICAL LABORATORY INSTRUMENT MANUFACTURING 334516 | GLADSTONE CYTOMETRY FOR VA SAN FRANCISCO | $4,075 |
| 2025 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | TARGETING TAT/TAR INTERACTIONS WITH THE SUPERELONGATION COMPLEX TO DEVELOP NOVEL TREATMENTS FOR HIV/AIDS - PROJECT SUMMARY (ABSTRACT) DESPITE THE REMARKABLE SUC | -$52 |
| 2025 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | DECONSTRUCTING EPILEPTIC CIRCUITS IN A MOUSE MODEL OF SLC6A1 SYNDROME - PROJECT SUMMARY & ABSTRACT THE SLC6A1 GENE HAS BEEN RECENTLY IMPLICATED IN A SPECTRUM O | -$6,095 |
| 2025 | Department of Veterans Affairs | Contract | ANALYTICAL LABORATORY INSTRUMENT MANUFACTURING 334516 | FLOW CYTOMETER CORE USE FOR THE RESEARCH DEPT. | -$6,375 |
| 2025 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | EXPLOITING THE HOST-HIV INTERFACE TO IDENTIFY BIOMARKERS PREDICTING TIME TO VIRAL REBOUND AFTER TREATMENT INTERRUPTION | -$22,366 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | MALIGNANT CELL ENGAGEMENT IN IMMUNE CIRCUITS OF HUMAN MICROSATELLITE-STABLE AND MICROSATELLITE-INSTABLE COLORECTAL CANCER - PROJECT SUMMARY AN IMPORTANT QUESTIO | -$63,841 |
| 2025 | National Institutes of Health | Grant or other assistance | CANCER RESEARCH MANPOWER 93.398 | EXPANDING THE SCOPE OF PROTEIN DEGRADATION AND STABILITY USING CHEMOPROTEOMIC PLATFORMS - TARGETED PROTEIN DEGRADATION (TPD) HAS ARISEN AS A POWERFUL DRUG DISCO | -$92,430 |
| 2025 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | PROTEOMIC AND GENETIC APPROACHES DEFINING APOLIPOPROTEIN E4 NEUROPATHOLOGIC MECHANISMS | -$333,354 |
| 2024 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | VASCULAR-IMMUNE MECHANISMS OF CEREBRAL AMYLOID ANGIOPATHY AND ALZHEIMER'S PATHOLOGY - COGNITIVE DECLINE IN THE AGING BRAIN IS DRIVEN BY OVERLAPPING NEURODEGENER | $5,423,836 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | HOPE - HIV OBSTRUCTION BY PROGRAMMED EPIGENETICS - PROJECT SUMMARY/ABSTACT AFTER 40 YEARS, A CURE FOR PEOPLE LIVING WITH HIV (PLWH) REMAINS BOTH ELUSIVE AND ONE | $5,336,026 |
| 2024 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | DECODING THE MULTIFACTORIAL ETIOLOGY OF NEURAL NETWORK DYSFUNCTION IN ALZHEIMER'S DISEASE - SUPPLEMENT – SUMMARY TAU CONTRIBUTES TO ALZHEIMER’S DISEASE (AD) AND | $4,657,774 |
| 2024 | Defense Health Agency | Grant or other assistance | MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 | DEVELOPING A PRACTICAL FORM OF HYPOXIA THERAPY FOR MITOCHONDRIAL DISEASES SUCH AS 3-MGA. | $3,024,000 |
| 2024 | National Institutes of Health | Grant or other assistance | DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS 93.279 | SORTING AND SEQUENCING LATENT RESERVOIRS IN HIV+ OPIOID USERS - ABSTRACT OPIOID USERS ARE PRIME BENEFICIARIES OF CURE STRATEGIES FOR HIV DUE TO THEIR MEDICAL AN | $1,560,507 |
| 2024 | National Institutes of Health | Grant or other assistance | TRANS-NIH RESEARCH SUPPORT 93.310 | SINGLE-CELL CHEMICAL TRANSCRIPTOMIC DISSECTION OF AN ESSENTIAL TRANSCRIPTION FACTOR NETWORK - PROJECT SUMMARY / ABSTRACT BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER T | $1,134,000 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | MODULATING STOCHASTIC GENE EXPRESSION FOR CELL-FATE CONTROL AND THERAPEUTICS - PROJECT SUMMARY STOCHASTIC FLUCTUATIONS IN GENE EXPRESSION ARE UNAVOIDABLE AT THE | $1,014,080 |
| 2024 | National Institutes of Health | Grant or other assistance | DRUG USE AND ADDICTION RESEARCH PROGRAMS 93.279 | A GENE DRIVE THERAPY FOR HIV: SINGLE-ADMINISTRATION INTERVENTION FOR HIGH-RISK GROUPS | $945,000 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | TARGETING FEEDBACK CIRCUITRY FOR ANTIVIRAL THERAPY - PROJECT SUMMARY/ABSTRACT THE HUMAN HERPESVIRUS 5 (CYTOMEGALOVIRUS, CMV) INFECTS >50% OF THE WORLD’S POPULAT | $944,989 |
| 2024 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | DEVELOP AD CONNECTIVITY MAPS WITH HUMAN IPSC-DERIVED BRAIN CELLS AND THEIR USE - SUMMARY ALZHEIMER’S DISEASE (AD) IS A MULTIFACTORIAL NEURODEGENERATIVE DISORDER | $941,764 |
| 2024 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | STUDY ALZHEIMER'S DISEASE PROTECTIVE APOE VARIANTS - PROJECT SUMMARY THE COMPLEXITY AND MULTIFACTORIAL NATURE OF ALZHEIMER’S DISEASE (AD) POSE UNIQUE CHALLENGES | $941,364 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | TARGETING THE TRANSCRIPTIONALLY-ACTIVE RESERVOIR TO REDUCE CHRONIC INFLAMMATION IN AGED PEOPLE WITH HIV - PROJECT SUMMARY RECENT DATA SUGGEST THAT A SUBSTANTIA | $915,998 |
| 2024 | National Institutes of Health | Grant or other assistance | HUMAN GENOME RESEARCH 93.172 | METHODS TO BUILD AND ANNOTATE TISSUE ATLASES USING SPATIAL GENOMIC DATA - PROJECT SUMMARY/ABSTRACT SINGLE-CELL SPATIAL TECHNOLOGIES HOLD THE PROMISE OF UNDERSTA | $829,659 |
| 2024 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | NEURONAL APOE DRIVES SELECTIVE NEURODEGENERATION IN ALZHEIMER'S DISEASE - PROJECT SUMMARY SELECTIVE NEURODEGENERATION IS A CRITICAL CAUSAL FACTOR IN ALZHEIMER’S | $817,317 |
| 2024 | Defense Health Agency | Grant or other assistance | MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 | GENETIC VARIANTS CONFERRING SUSCEPTIBILITY TO TOXICANT-INDUCED PARKINSON'S DISEASE | $811,942 |
| 2024 | National Institutes of Health | Grant or other assistance | TRANS-NIH RESEARCH SUPPORT 93.310 | CARDIOGENESIS: MOLECULAR MECHANISMS | $787,185 |
| 2024 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | SMALL MOLECULE THERAPEUTIC FOR CALCIFIC AORTIC VALVE DISEASE - PROJECT SUMMARY AORTIC VALVE STENOSIS IS THE MAJOR CAUSE OF VALVE DISEASE IN THE WESTERN WORLD, A | $782,141 |
| 2024 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | MODELING INTESTINAL DYSFUNCTION IN HIV INFECTION WITH ORGANOID TECHNOLOGY | $758,173 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | ROLE OF FACTOR ACETYLATION IN THE REGULATION OF HIV TRANSCRIPTION | $737,100 |
| 2024 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | STUDY THE PROTECTIVE ROLES OF APOE2 IN ALZHEIMER'S DISEASE USING REPROGRAMMED ISOGENIC CELLS | $724,286 |
| 2024 | National Institutes of Health | Grant or other assistance | TRANS-NIH RESEARCH SUPPORT 93.310 | GENETIC DETERMINANTS OF 4D GENOME FOLDING IN HUMAN CARDIAC DEVELOPMENT | $719,990 |
| 2024 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | DECODING AND REPROGRAMMING T CELLS THROUGH SYNTHETIC BIOLOGY FOR CANCER IMMUNOTHERAPY - ABSTRACT ENGINEERED T CELL-BASED CANCER THERAPIES ARE A MAJOR ADVANCEMEN | $711,787 |
| 2024 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | C9ORF72 FRONTOTEMPORAL DEMENTIA (FTD) AND AMYOTROPHIC LATERAL SCLEROSIS(ALS): USING PATIENT CELLS AND CRISPR TO REVEAL THERAPEUTIC APPROACHES - PROJECT SUMMARY/ | $708,750 |
| 2024 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | MULTIOMICS CHARACTERIZATION, INDUCTION, AND ELIMINATION OF THE HIV GUT RESERVOIR - PROJECT SUMMARY STUDIES IN ANIMAL MODELS HAVE SUGGESTED 98% OF THE HIV RESER | $695,727 |
| 2024 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | LINKING MICROBIOME GENETIC VARIANTS WITH CARDIOVASCULAR PHENOTYPES IN 50,000 INDIVIDUALS - PROJECT SUMMARY / ABSTRACT THE HUMAN BODY IS HOME TO A COMPLEX COMMUN | $671,307 |
| 2024 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | CELL AND NETWORK DISRUPTIONS AND ASSOCIATED PATHOGENENESIS IN TAUOPATHY AND DOWN SYNDROME | $641,436 |
| 2024 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | DEFINING STRATEGIES TO TARGET ENERGY FAILURE IN METABOLICALLY VULNERABLE HUMAN CELLS | $620,722 |
| 2024 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | GENE REGULATORY NETWORKS FOR HEART DEVELOPMENT - PROJECT SUMMARY CONGENITAL HEART DEFECTS (CHDS) ARE THE MOST PREVALENT AND SERIOUS BIRTH DEFECTS, OCCURRING IN | $588,099 |
| 2024 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | EARLY CARDIAC PROGENITORS | $553,585 |
| 2024 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | ROLE OF MYELOID AND CD4+ T IMMUNE CELLS IN POST-TRAUMATIC PLASTICITY - ABSTRACT TRAUMATIC BRAIN INJURY (TBI) IMPACTS MILLIONS OF AMERICANS EACH YEAR AND CAN LEA | $543,669 |
| 2024 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | A TRANSLATABLE FORM OF HYPOXIA THERAPY FOR IMPAIRED MITOCHONDRIAL PROTEOSTASIS - PROJECT ABSTRACT OUR PREVIOUS WORK DEMONSTRATED THAT HYPOXIC BREATHING, SIMULAT | $472,500 |
| 2024 | National Institutes of Health | Grant or other assistance | TRANS-NIH RESEARCH SUPPORT 93.310 | SELF-ASSEMBLING SPIKE-EBR NANOPARTICLES AS A VACCINE PLATFORM TECHNOLOGY AGAINST SARS-COV-2 AND FUTURE PANDEMIC CORONAVIRUSES. - PROJECT SUMMARY/ABSTRACT THE CO | $472,500 |
| 2024 | National Institutes of Health | Grant or other assistance | TRANS-NIH RESEARCH SUPPORT 93.310 | TRANSFER LEARNING LEVERAGING LARGE-SCALE TRANSCRIPTOMICS TO MAP DISRUPTED GENE NETWORKS IN CARDIOVASCULAR DISEASE - PROJECT SUMMARY/ABSTRACT MAPPING THE GENE RE | $472,500 |
| 2024 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | OPC-X SCREEN: DISCOVERY OF SMALL MOLECULE INHIBITORS TO OVERCOME EXTRINSIC INHIBITION OF REMYELINATION. - PROJECT SUMMARY/ABSTRACT MULTIPLE SCLEROSIS (MS) IS A | $458,325 |
| 2024 | National Institutes of Health | Grant or other assistance | MEDICAL LIBRARY ASSISTANCE 93.879 | IMAGE TOOLS FOR COMPUTATIONAL CELLULAR BARCODING AND AUTOMATED ANNOTATION - PROJECT SUMMARY WITH TECHNOLOGICAL BREAKTHROUGHS IN HIGH-THROUGHPUT SINGLE-CELL IMAG | $398,349 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | TARGETING CD127-EXPRESSING TISSUE RESERVOIR CELLS AS A STRATEGY FOR HIV CURE - PROJECT SUMMARY HOMEOSTATIC PROLIFERATION, IN PARTICULAR THAT MEDIATED BY IL7, I | $250,791 |
| 2024 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | TARGETED DELIVERY OF CAS9 TO LUNG EPITHELIAL CELLS USING ENVELOPED DELIVERY VEHICLES - PROJECT SUMMARY/ABSTRACT THE RAPID DEVELOPMENT OF GENOME EDITING TOOLS HA | $236,250 |
| 2024 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | ADDRESSING DISPARITIES IN POLYGENIC RISK SCORE FOR CORONARY HEART DISEASES IN DIVERSE POPULATIONS - PROJECT SUMMARY/ABSTRACT CORONARY HEART DISEASE (CHD) REMAIN | $179,280 |
| 2024 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | PROMOTING UNDERREPRESENTED MINORITY ADVANCEMENT IN THE SCIENCES (PUMAS) | $166,320 |
| 2024 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | MACHINE LEARNING APPROACHES FOR BEHAVIORAL PHENOTYPING OF HUMANIZED KNOCK-IN MODELS OF ALZHEIMER'S DISEASE - PROJECT SUMMARY PRECLINICAL EFFORTS TO DEVELOP TREA | $150,630 |
| 2024 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | METABOLIC VULNERABILITY AND EFFECTS OF APOE IN HUMAN NEURONS WITH IMPAIRED ENDOCYTIC RECYCLING - PROJECT SUMMARY NEURODEGENERATIVE DEMENTIAS, INCLUDING ALZHEIME | $130,950 |
| 2024 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | UNDERSTANDING HOW NEURONAL GLUCOSE METABOLISM CHANGES IN AD DUE TO APOE4 - PROJECT SUMMARY WITH RAPID IMPROVEMENTS TO THE QUALITY OF OUR HEALTHCARE, THERE IS AN | $81,364 |
| 2024 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | CELLULAR PERTURBATIONS TO ENHANCE PRECISE THERAPEUTIC GENOME EDITING TO TREAT FTD/ALS - PROJECT SUMMARY CRISPR HOLDS GREAT PROMISE TOWARD THERAPEUTICALLY EDITI | $74,284 |
| 2024 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | INVESTIGATION INTO TRANSCRIPTOMIC CONTROL OF DENTATE GRANULE CELL MATURATION AND HYPEREXCITABILITY IN THE APOE4 ALZHEIMER'S DISEASE MODEL - PROJECT SUMMARY ALZH | $74,284 |
| 2024 | National Institutes of Health | Grant or other assistance | CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 | TRANSCRIPTIONAL VARIATION IN HUMAN MILK - PROJECT SUMMARY THE CENTERS FOR DISEASE CONTROL RECOMMENDS BREASTFEEDING FOR THE FIRST SIX MONTHS OF AN INFANT’S LIFE | $69,080 |
| 2024 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | DECONSTRUCTING EPILEPTIC CIRCUITS IN A MOUSE MODEL OF SLC6A1 SYNDROME - PROJECT SUMMARY & ABSTRACT THE SLC6A1 GENE HAS BEEN RECENTLY IMPLICATED IN A SPECTRUM O | $36,647 |
| 2024 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | AMERICAN SOCIETY FOR NEURAL THERAPY AND REPAIR ANNUAL CONFERENCE - ABSTRACT THIS R13 APPLICATION SEEKS FUNDING FOR OUR ANNUAL AMERICAN SOCIETY FOR NEURAL THERAP | $25,000 |
| 2024 | Department of Veterans Affairs | Contract | ANALYTICAL LABORATORY INSTRUMENT MANUFACTURING 334516 | FY24-FY25 FLOW CYTOMETER CORE USE FOR RESEARCH | $21,726 |
| 2024 | Department of Veterans Affairs | Contract | ANALYTICAL LABORATORY INSTRUMENT MANUFACTURING 334516 | FLOW CYTOMETER CORE USE FOR THE RESEARCH DEPT. | $10,375 |
| 2024 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | NEURAL NETWORK AND IMMUNE CELL DYSFUNCTIONS IN ALZHEIMER'S DISEASE PATHOGENESIS | -$1,922 |
| 2024 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | EXPLOITING THE HOST-HIV INTERFACE TO IDENTIFY BIOMARKERS PREDICTING TIME TO VIRAL REBOUND AFTER TREATMENT INTERRUPTION | -$22,366 |
| 2024 | National Institutes of Health | Grant or other assistance | TRANS-NIH RESEARCH SUPPORT 93.310 | HUMAN MICROTISSUES FOR IN SITU DETECTION AND FUNCTIONAL MEASUREMENT OF ADVERSE CONSEQUENCES CAUSED BY GENOME EDITING | -$27,785 |
| 2024 | Defense Health Agency | Grant or other assistance | MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 | PHASE 1 CLINICAL TRIAL FOR THERAPEUTIC INTERVENTION PARTICLES (TIPS). | -$1,920,342 |
| 2023 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | HOPE - HIV OBSTRUCTION BY PROGRAMMED EPIGENETICS - PROJECT SUMMARY/ABSTACT AFTER 40 YEARS, A CURE FOR PEOPLE LIVING WITH HIV (PLWH) REMAINS BOTH ELUSIVE AND ONE | $6,334,269 |
| 2023 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | DECODING THE MULTIFACTORIAL ETIOLOGY OF NEURAL NETWORK DYSFUNCTION IN ALZHEIMER'S DISEASE - SUPPLEMENT – SUMMARY TAU CONTRIBUTES TO ALZHEIMER’S DISEASE (AD) AND | $4,722,729 |
| 2023 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | ROLES OF TREM2 AND TYROBP IN AD-RELATED NETWORK HYPEREXCITABILITY - SUMMARY RECENT EVIDENCE SUGGESTS THAT IMMUNE AND NEURAL NETWORK DYSFUNCTIONS FORM A VICIOUS | $2,833,089 |
| 2023 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | COMBINATORIAL REGULATION OF GENE NETWORKS DURING CARDIAC DEVELOPMENT AND DISEASE | $2,723,920 |
| 2023 | National Institutes of Health | Grant or other assistance | DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS 93.279 | SORTING AND SEQUENCING LATENT RESERVOIRS IN HIV+ OPIOID USERS - ABSTRACT OPIOID USERS ARE PRIME BENEFICIARIES OF CURE STRATEGIES FOR HIV DUE TO THEIR MEDICAL AN | $1,630,854 |
| 2023 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | NEUROVASCULAR INTERACTIONS: MECHANISMS, IMAGING, THERAPEUTIC POTENTIAL | $1,415,966 |
| 2023 | National Institutes of Health | Grant or other assistance | DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS 93.279 | A GENE DRIVE THERAPY FOR HIV: SINGLE-ADMINISTRATION INTERVENTION FOR HIGH-RISK GROUPS | $1,132,110 |
| 2023 | National Institutes of Health | Grant or other assistance | DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS 93.279 | SINGLE-CELL TRANSCRIPTOMICS OF NON-ACTIVATED LATENTLY INFECTED T CELLS ISOLATED FROM HIV+ DRUG USERS - SINGLE-CELL TRANSCRIPTOMICS OF NON-ACTIVATED LATENTLY INF | $941,806 |
| 2023 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | DEVELOP AD CONNECTIVITY MAPS WITH HUMAN IPSC-DERIVED BRAIN CELLS AND THEIR USE - SUMMARY ALZHEIMER’S DISEASE (AD) IS A MULTIFACTORIAL NEURODEGENERATIVE DISORDER | $941,764 |
| 2023 | National Institutes of Health | Grant or other assistance | ALLERGY AND INFECTIOUS DISEASES RESEARCH 93.855 | MODULATING STOCHASTIC GENE EXPRESSION FOR CELL-FATE CONTROL AND THERAPEUTICS - PROJECT SUMMARY STOCHASTIC FLUCTUATIONS IN GENE EXPRESSION ARE UNAVOIDABLE AT THE | $918,446 |
| 2023 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | NEURONAL APOE DRIVES SELECTIVE NEURODEGENERATION IN ALZHEIMER'S DISEASE - PROJECT SUMMARY SELECTIVE NEURODEGENERATION IS A CRITICAL CAUSAL FACTOR IN ALZHEIMER’S | $817,317 |
| 2023 | National Institutes of Health | Grant or other assistance | TRANS-NIH RESEARCH SUPPORT 93.310 | CARDIOGENESIS: MOLECULAR MECHANISMS | $803,250 |
| 2023 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | SMALL MOLECULE THERAPEUTIC FOR CALCIFIC AORTIC VALVE DISEASE - PROJECT SUMMARY AORTIC VALVE STENOSIS IS THE MAJOR CAUSE OF VALVE DISEASE IN THE WESTERN WORLD, A | $798,104 |
| 2023 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | MODELING INTESTINAL DYSFUNCTION IN HIV INFECTION WITH ORGANOID TECHNOLOGY | $789,764 |
| 2023 | National Institutes of Health | Grant or other assistance | CANCER BIOLOGY RESEARCH 93.396 | DECODING AND REPROGRAMMING T CELLS THROUGH SYNTHETIC BIOLOGY FOR CANCER IMMUNOTHERAPY - ABSTRACT ENGINEERED T CELL-BASED CANCER THERAPIES ARE A MAJOR ADVANCEMEN | $771,499 |
| 2023 | National Institutes of Health | Grant or other assistance | DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 | MULTIOMICS CHARACTERIZATION, INDUCTION, AND ELIMINATION OF THE HIV GUT RESERVOIR - PROJECT SUMMARY STUDIES IN ANIMAL MODELS HAVE SUGGESTED 98% OF THE HIV RESER | $725,170 |
| 2023 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | STUDY THE PROTECTIVE ROLES OF APOE2 IN ALZHEIMER'S DISEASE USING REPROGRAMMED ISOGENIC CELLS | $724,286 |
| 2023 | National Institutes of Health | Grant or other assistance | TRANS-NIH RESEARCH SUPPORT 93.310 | GENETIC DETERMINANTS OF 4D GENOME FOLDING IN HUMAN CARDIAC DEVELOPMENT | $719,990 |
| 2023 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | DECIPHERING MOLECULAR PATHWAYS OF INHIBITORY INTERNEURON DYSFUNCTION IN ALZHEIMER'S DISEASE | $712,548 |
| 2023 | National Institutes of Health | Grant or other assistance | DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS 93.279 | EXPLORING HIV-ASSOCIATED NEUROCOGNITIVE DISORDER (HAND) AND HIV LATENCY AT THE SINGLE CELL LEVEL IN CEREBRAL ORGANOIDS | $708,000 |
| 2023 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | LINKING MICROBIOME GENETIC VARIANTS WITH CARDIOVASCULAR PHENOTYPES IN 50,000 INDIVIDUALS - PROJECT SUMMARY / ABSTRACT THE HUMAN BODY IS HOME TO A COMPLEX COMMUN | $685,007 |
| 2023 | National Institutes of Health | Grant or other assistance | CARDIOVASCULAR DISEASES RESEARCH 93.837 | AORTIC VALVE DISEASE: MECHANISMS AND THERAPEUTIC APPROACHES | $679,124 |
| 2023 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | APOLIPOPROTEIN E4-RELATED ELECTROPHYSIOLOGICAL AND METABOLIC IMPAIRMENTS IN AGING AND ALZHEIMER'S DISEASE | $655,674 |
| 2023 | National Institutes of Health | Grant or other assistance | AGING RESEARCH 93.866 | DEFINING STRATEGIES TO TARGET ENERGY FAILURE IN METABOLICALLY VULNERABLE HUMAN CELLS | $645,796 |
| 2023 | National Institutes of Health | Grant or other assistance | EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 | RARE VARIANT WHOLE GENOME ANALYSIS AND IPSC VALIDATION OF PUTATIVE GENETIC MODIFIERS OF HUNTINGTON DISEASE | $643,836 |
State business registration
- J. DAVID GLADSTONE INSTITUTES CO, FNC, Good Standing, formed 2026-03-03
The same business name in the same state, from the state’s official registry data.
Patents
72 US patents filed in the last 20 years.
- The J. David Gladstone Institutes 72 patents, 2009-06-09 to 2026-02-10 FUZZY medium confidence: same name (governing-board words and legal endings aside) and state
| Patent | Title | Granted | Source |
|---|---|---|---|
| US 12544348 | Methods for treating APOE4/4-associated disorders | 2026-02-10 | PTBLXML, file of 2026-02-10 |
| US 12522860 | Detection of genome editing | 2026-01-13 | PTBLXML, file of 2026-01-13 |
| US 12460230 | Modified mitochondrion and methods of use thereof | 2025-11-04 | PVGPATDIS, file of 2026-04-10 |
| US 12146166 | Generation of induced pluripotent cells by CRISPR activation | 2024-11-19 | PVGPATDIS, file of 2026-04-10 |
| US 11807852 | Compositions and methods for reactivating latent immunodeficiency virus | 2023-11-07 | PVGPATDIS, file of 2026-04-10 |
| US 11773051 | S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same | 2023-10-03 | PVGPATDIS, file of 2026-04-10 |
| US 11608308 | Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same | 2023-03-21 | PVGPATDIS, file of 2026-04-10 |
| US 11584931 | Methods and compositions for generating a deletion library and for identifying a defective interfering particle (DIP) | 2023-02-21 | PVGPATDIS, file of 2026-04-10 |
| US 11440948 | Modified non-natural NKG2D ligands that selectively deliver attached heterologous molecules to non-natural NKG2D receptors on car-cells | 2022-09-13 | PVGPATDIS, file of 2026-04-10 |
| US 11376242 | Methods and compositions for treating obesity and/or diabetes and for identifying candidate treatment agents | 2022-07-05 | PVGPATDIS, file of 2026-04-10 |
The newest patents of the PatentsView assignees above, matched to this record by name (and state).
Trademarks
3 US trademarks, 2 live.
- The Trustees of The J. David Gladstone Institutes 3 marks, CA FUZZY medium confidence: same name (governing-board words and legal endings aside) and state
| Mark | Serial | Filed | Status | Source |
|---|---|---|---|---|
| ROVIR | 90104743 | 2020-08-10 | Abandoned | TRTYRAP, file of 2026-04-03 |
| BIOFULCRUM | 88611751 | 2019-09-10 | Registered | TRTYRAP, file of 2026-04-03 |
| SCIENCE OVERCOMING DISEASE | 85490985 | 2011-12-08 | Registered and renewed | TRCFECO2, file of 2024-03-27 |
The newest marks of the trademark owners above, matched to this record by name (and state).
Comments